Molecular Mechanism of Incorporation of Factor Va into Prothrombinase by Barhoover, Melissa
Cleveland State University
EngagedScholarship@CSU
ETD Archive
2007
Molecular Mechanism of Incorporation of Factor
Va into Prothrombinase
Melissa Barhoover
Cleveland State University
Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Chemistry Commons
How does access to this work benefit you? Let us know!
This Dissertation is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for inclusion in ETD Archive by an
authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Recommended Citation
Barhoover, Melissa, "Molecular Mechanism of Incorporation of Factor Va into Prothrombinase" (2007). ETD Archive. 26.
https://engagedscholarship.csuohio.edu/etdarchive/26
 
 
 
 
MOLECULAR MECHANISM OF 
INCORPORATION OF FACTOR Va INTO 
PROTHROMBINASE 
 
 
 
 
MELISSA A. BARHOOVER 
 
 
Bachelor of Science in Chemistry 
 
Bowling Green State University 
 
May, 2000 
 
 
 
Submitted in partial fulfillment of requirements for the degree 
DOCTOR OF PHILOSOPHY IN CLINICAL AND BIOANALYTICAL 
CHEMISTRY 
at the 
CLEVELAND STATE UNIVERSITY 
December, 2007 
 
 
This dissertation has been approved for the Department of Chemistry and the College 
of Graduate Studies by: 
 
Dr. Michael Kalafatis ___________________________________________________ 
Dissertation Committee Chairperson 
 
    _________________________ 
Department & Date 
 
 
Dr. Lily Ng ___________________________________________________________ 
Dissertation Committee Member 
 
    _________________________ 
Department & Date 
 
 
Dr. Amin Zhou ________________________________________________________ 
Dissertation Committee Member 
 
    _________________________ 
Department & Date 
 
 
Dr. Harry VanKeulen ___________________________________________________ 
Dissertation Committee Member 
 
    _________________________ 
Department & Date 
 
 
Dr. Xue-Long Sun _____________________________________________________ 
Dissertation Committee Member 
 
    _________________________ 
Department & Date 
 
 
Dr. David Anderson ____________________________________________________ 
Dissertation Committee Member 
 
    _________________________ 
Department & Date 
 
ACKOWLEDGEMENT 
 
     I would like to dedicate this dissertation to my husband, Bryon, who has been my 
emotional backbone.  Thanks for your endless love and support.   I would also like to 
thank my family and friends; especially my sister, Rachel, and best friends, Beth and 
Ronda, who have always provided an open ear and shoulder to lean on. 
    There have been many people who have helped my during my studies and I cannot 
thank them enough for their support; 
     First, I would like to thank my research advisor and mentor, Dr. Michael Kalafatis, 
for his scientific insight and hours of work he has spent with me on my project.  His 
expertises in the field of coagulation and enthusiasm have made this research 
possible.  It is an honor and privilege to graduate from his research group. 
     I would also like to thank the members of my dissertation committee for their 
helpful insight and critique of my research project: Drs. David Anderson, Lily Ng, 
Xue-Long Sun, Harry VanKeulen, and Amin Zhou.  I would like to thank Richelle 
Emery and Michelle Jones in the Chemistry office for their administrative support 
over the years. 
     I would especially like to thank the members of my research group, Michael 
Bukys, Jamila Hirbawi, Dr. Alieta Ciocea, Tivadar Orban, Kerri Smith, and Dr. 
Evrim Erdogan for their emotional and technical support.  I would also like to thank 
all the fellow graduate students and staff at Cleveland State University. 
 
 iv
MOLECULAR MECHANISM OF 
INCORPORATION OF FACTOR Va INTO 
PROTHROMBINASE 
 
MELISSA A. BARHOOVER 
 
ABSTRACT 
 
     The mainstay of the blood coagulation cascade is the formation of the fibrin clot, 
catalyzed by the serine protease, thrombin.  The prothrombinase complex is 
composed of the enzyme, factor Xa, and the protein cofactor, factor Va, in the 
presence of divalent metal ions associated on a membrane surface.  This complex 
catalyzes the activation of prothrombin to its active form, thrombin.  The enzyme, 
factor Xa, alone can activate prothrombin by two sequential proteolytic cleavages at 
Arg271 and Arg320 resulting in the intermediates, Fragment 1.2 and Prethrombin 2.  
The overall rate of this reaction is not compatible with survival.  On the other hand, 
the incorporation of an excess of the cofactor, factor Va, into prothrombinase reverses 
the order of the proteolytic cleavages and increases the catalytic activity of factor Xa 
by 5 orders of magnitude, making this reaction compatible with survival.  While the 
importance of the contribution of factor Va to the activity of factor Xa for rapid 
thrombin formation by prothrombinase at the place of vascular injury has been long 
established, the consequence of the interaction of the cofactor with the members of 
prothrombinase and the molecular mechanism by which factor Va accelerates 
prothrombin activation remains an enigma. 
 v
     The LONG-TERM goal of this research is to characterize the physiological 
mechanism by which the prothrombinase complex promotes blood coagulation with 
the aim of providing a template for the synthesis of small molecules to be used as 
anti-coagulants in-vivo. 
     The SHORT-TERM goal of this research is to identify the precise amino acids of 
the central portion of the factor Va heavy chain involved in its incorporation into the 
prothrombinase complex and the cofactor function it exerts on the catalytic efficiency 
of prothrombin activation.   
     Our hypothesis is that the incorporation of the factor Va heavy chain is mediated 
through a binding site for prothrombin and/or thrombin and through a binding site 
for factor Xa causing factor Xa to express a cryptic exosite for prothrombin which 
increases the catalytic efficiency of factor Xa. 
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CHAPTER I 
 
INTRODUCTION 
 
 
1.1 Prevalence of Cardiovascular Disease and Stroke 
          Heart disease is defined as any disorder of the cardiovascular system (an organ 
system composed of the heart and blood vessels that move substances to and from 
cells helping to stabilize body temperature and pH), which affects the heart’s 
capability to function regularly.  Cardiovascular or heart disease is the foremost cause 
of death in men and women in the United States and is also a major cause of death 
throughout the rest of the world.  It has been approximated that over 61 million 
Americans have heart disease, and 950 thousand of people with this condition die 
each year; accounting for almost 40% of all deaths in the United States.  In addition, 
according to the American Heart Association, cardiovascular disease is responsible 
for more deaths in women than the next six leading causes of death combined.  
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Moreover, the third leading cause of death in adults in the United States is stroke.  
Research performed by the American Heart Association shows that nearly 700,000 
people suffer from a stroke each year and over 150,000 of these patients die.  Today, 
5.7 million Americans are stroke survivors suffering from permanent stroke-related 
disabilities. A thrombotic stroke, a type of ischemic stroke, occurs when a blood clot 
develops in an artery and gradually narrows the lumen of the artery eventually 
leading to impeding of blood flow.  In time, the clot will break off and partially or 
totally cut off blood supply to the brain. 
1.1.1 Deep Vein Thrombosis 
    Deep Vein Thrombosis, or DVT, is a condition that results from the formation of a 
blood clot, or thrombus, located inside a deep vein commonly in the calf or thigh.  
There are three main causes of DVT: 1, stasis or slowing of blood flow defects, 2, a n 
disproportion among clot-promoting and clot-preventing factors, and 3, defects found 
in the vein wall.  DVT takes place when the thrombus partially or completely blocks 
the flow of blood in the deep vein.  When the thrombus completely blocks the flow of 
blood, it causes blood below the blockage to back up and cause more stasis.  A major 
complication associated with DVT is an embolism; which happens when a part of the 
thrombus breaks off and travels in the blood stream.  A pulmonary embolism is when 
the thrombus travels and becomes lodged in an artery in the lung; blood that goes to 
the lungs to become oxygenated brings the clot with it, thus blocking the blood flow. 
1.1.2 Anti-Coagulant Drug Therapy 
     It has been demonstrated that heart disease is the number one killer in the United 
States and has been for almost a century.  Survivors of this disease are often 
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prescribed anti-coagulants as treatment, which are frequently accompanied by serious 
side effects; including fatal or nonfatal hemorrhage, purple toes syndrome, nausea, 
loss of appetite, headache, joint or muscle pain, etc.  The current anti-coagulants 
administered are non-specific serine protease inhibitors.  Many of the proteases 
involved in the blood coagulation cascade are serine proteases.  In addition, there are 
serine proteases involved in signaling pathways, enzyme activation, and degradative 
functions in different cellular or extra cellular compartments.   
     The most widely used anti-coagulant today is coumadin (warfarin).  Coumadin 
was actually first developed as a rat poison.  Coumadin is referred to as a vitamin K 
antagonist, as it decreases blood coagulation by impeding vitamin K metabolism (1).  
Vitamin K plays a fundamental role in the activity of vitamin K dependent serine 
proteases.  It operates as a cofactor for the carboxylase catalyzed conversion of 
certain glutamic acid residues into γ-carboxyglutamic acid during their biosynthesis 
in the liver.  These adapted amino acid residues are required for membrane binding of 
both enzymes and substrates in order to form the enzymatic complexes necessary for 
coagulation (2).  Coumadin interferes with the γ-carboxylation of vitamin K 
dependent serine proteases, and the resultant in vivo effect is a sequential depression 
of Factors VII, IX, X and II activities.  Since there are so many vitamin K dependent 
serine proteases involved in the blood coagulation cascade and other pathways; it is, 
therefore, important to understand the specific regulation of the blood-clotting 
cascade in order to design a drug that does not have these serious side effects. 
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1.2 Hemostasis 
     Hemostasis is the physiological process whereby bleeding is halted (procoagulant) 
and thrombosis is the formation or presence of a blood clot within a blood vessel or 
one of the cavities in the heart (anticoagulant). Hemostasis is defined as the 
equilibrium between procoagulant and anticoagulant systems that function in concert 
to maintain the fluidity of blood under physiological conditions. The onset of 
hemostasis is initiated when there is an injury to the vasculature and several steps 
occur to stop vessel bleeding.  Directly following the injury there is an immediate 
response that promotes vasoconstriction (narrowing of the lumen of the blood vessel), 
formation of the platelet plug, blood coagulation, and ultimate healing of the injured 
vessel.   Hemostasis takes place through primary and secondary hemostatic events.  
Immediately following injury, primary hemostasis begins.  When circulating platelets 
bind to collagen exposed at the site of vasculature injury.  Platelets are cell fragments 
that are produced in the bone marrow and circulate in plasma.  The binding of 
platelets to the site of injury forms the hemostatic plug within seconds after injury.  
Secondary hemostasis is the complex process of blood coagulation involving the 
regulated interaction of proteases, zymogens, cofactors, and inhibitors presented to 
the site of vasculature injury in the blood by platelets, blood cells, and the vessel wall 
(Figure 1.1). 
1.3 Blood Coagulation Cascade 
     The result of the coagulation cascade is the formation of the fibrin clot.  The clot 
attracts and stimulates the growth of fibroblasts and smooth muscle cells within the 
vessel wall, and begins the repair process, which ultimately results in the dissolution  
 5
 
 
 
Figure 1.1:  Schematic of the blood coagulation cascade.  Two separate pathways, 
either the intrinsic pathway or the extrinsic pathway can initiate the cascade.  These 
two pathways merge to a common pathway, the activation of prothrombin to 
thrombin, leading to the formation of the fibrin plug (taken from 
www.kingsnake.com). 
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of the clot, a process defined as fibrinolysis.  These events must stay localized to the 
damaged site or clots may occur throughout the vasculature resulting in the occlusion 
of blood flow to tissues and organs possibly leading to the damaging effects of heart 
disease and stroke.  
1.3.1 The Extrinsic Pathway 
     In the Extrinsic pathway (tissue factor pathway), following injury there is 
exposure of an integral membrane glycoprotein, tissue factor, which then forms a 
complex with the enzyme factor VIIa.  Only a small portion of factor VII circulates in 
its active form, factor VIIa (3).  More factor VIIa is produced by proteolytic cleavage 
at residue Arg152 by thrombin, factor IXa, factor Xa, factor VIIa, and factor XIIa (4).  
The tissue factor/factor VIIa complex initiates the blood coagulation cascade by 
activating factor Xa.  This cell-associated enzymatic complex increases the 
generation of factor Xa by a factor of 30,000.  Factor VIIa also activates factor IX in 
the presence of tissue factor, providing a connection between the Extrinsic and 
Intrinsic pathways. 
1.3.2 The Intrinsic Pathway 
     The second pathway of blood coagulation is the Intrinsic pathway (contact 
pathway).  This pathway is initiated when several plasma proteins become activated 
when exposed to negatively charged membrane surfaces following damage to the 
vasculature.  The assemblage of contact phase components results in conversion of 
prekallikrein to kallikrein, which in turn activates factor XII to factor XIIa (5). Factor 
XIIa can then hydrolyze more prekallikrein to kallikrein, establishing a reciprocal 
activation cascade. Factor XIIa also activates factor XI to factor XIa and leads to the 
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release of bradykinin, a potent vasodilator, from high-molecular-weight kininogen.  
In the presence of Ca2+, factor XIa activates factor IX to factor IXa. Active factor IXa 
cleaves factor X at an internal arg-ile bond leading to its activation to factor Xa (6).   
1.3.3 The Common Pathway 
     The two pathways meet and become common upon the activation of factor Xa and 
the formation of the prothrombinase complex.  It is the prothrombinase complex, 
composed of the enzyme (factor Xa) the cofactor (factor Va) and the substrate 
(prothrombin), in the presence of calcium ions and a membrane surface, that activates 
prothrombin to thrombin.  Even though both the Intrinsic and Extrinsic pathways aid 
in the production of factor Xa, it has been demonstrated that it is the Intrinsic pathway 
that produces the bulk of factor Xa necessary for coagulation (7).  The 
prothrombinase complex activates prothrombin to its active form, thrombin.  In turn, 
thrombin will then convert fibrinogen to fibrin to form the clot. 
1.3.4 Initiation of Coagulation 
     When the coagulation cascade is initiated, production of thrombin is said to occur 
in three discrete phases (3, 8).  In the first phase, the initiation phase, when the 
cascade is started it leads to the formation of various active complexes (extrinsic 
tenase, intrinsic tenase, and prothrombinase) and low levels of thrombin production 
are detected.  At the end of this phase of coagulation, the propagation phase begins 
with thrombin generation at much higher levels.  Once enough thrombin is produced 
to form the fibrin clot, the termination phase of coagulation begins.  Throughout this 
phase, inhibition of the coagulation proteases begins due to the inhibitors Tissue 
Factor Pathway Inhibitor (TFPI) and Anti-thrombin (AT).  Feedback inhibition of the 
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cofactor, factor Va, via the protein C pathway also occurs (9-12).  These inhibition 
mechanisms limit the amount of active thrombin. 
1.4 Clinical Consequences of Deficiencies or Mutations in Clotting Cofactors 
      The importance of cofactors to the blood coagulation cascade is portrayed by the 
deficiency or mutation of the cofactors, factor V/Va and factor VIII/VIIIa.  When 
mutations occur in these proteins, it results in bleeding disorders.  
1.4.1 Factor VIII and Hemophilia 
     .  Hemophilia A is the result of a deficiency in factor VIII.  A variety of point 
mutations have been characterized in the factor VIII gene (13).  Individuals with these 
defects suffer prolonged bleeding times and often need infusions of factor VIII.  The 
severity of hemophilia A can range from mild to moderate to severe depending on the 
levels of factor VIII in plasma.  There has been over 150 point mutations identified in 
the factor VIII gene associated with hemophilia A.  Although, 90% of hemophilia 
cases are caused by deficiencies in factor VIII, hemophilia B is caused by a lack of 
factor IX and hemophilia C is caused by a lack of clotting factor XI. 
1.5 Coagulation Cofactor Factor V and activation by thrombin 
     Human factor V is a single chain glycoprotein (Mr = 330,000) present in plasma at 
a physiological concentration of 20nM (14).  It is composed of five domains; 
including three A domains, two C domains, and a B domain which connects these 
regions.  Factor V is activated by thrombin following three sequential cleavages at 
Arg709, Arg1018, and Arg1545 creating a heavy chain (Mr = 105,000) and a light chain 
(Mr = 74,000) associated non-covalently by divalent metal ions (Figure 1.2) (15).  The 
heavy chain is composed of two A domains, (residues 1-303 and residues 317-657), 
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which are connected by a region that is rich in basic amino acids.  The remaining 
portion of the heavy chain, residues 658-709, contains a cluster of acidic amino acids.  
The light chain also contains an A domain, residues 1546-1877, and two C domains, 
residues 1878-2036 and 2037-2196, respectively (16, 17)  The cleavage rates of 
Arg709 and Arg1018 are approximately equivalent, while cleavage at Arg1545 is 
somewhat delayed resulting in high molecular weight intermediates and a delayed 
appearance of the light chain (18).  It is this cleavage at Arg1545 that leads to fully 
active factor Va, indicating that formation of the light chain is an important step in 
factor V activation (19).  
1.5.1 Factor V Activation by other proteases 
     Factor V can also be activated by a number of venom proteases.  One such 
protease is an enzyme from Russell’s viper Venom (RVV-V).  RVV-V cleaves 
human factor V at two sites, Arg1018 and Arg1545, to create a heavy chain (Mr 150,000, 
residues 1-1018) and a light chain (Mr 74,000, residues 1546-2196).   This generates 
factor VaRVV-V which has similar activity as factor V activated by thrombin, factor 
VaIIa, and has similar affinity for factor Xa (20).  Factor V can also be cleaved by an 
enzyme from the venom of the snake Naja nigricollis nigricollis that cleaves factor V 
at Asp697, Asp1509, and Asp1514 which produces a heavy chain (Mr 100,000, residues 
1-696) and a light chain (Mr 80,000, residues 1509/1514-2196), designated factor 
VaNN.  Factor VaNN has 60-80% decreased clotting activity compared to factor VaIIa 
and has a decreased affinity for factor Xa with a Kd of 4nM (21).  Factor V activation 
by the snake venoms have further elucidated the mechanism of factor Va cofactor  
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Figure 1.2: Schematic of Factor V Activation by Thrombin. Factor V is activated 
by thrombin following three cleavages at Arg709, Arg1018, and Arg1545.   After 
cleavage of factor V at Arg709, the B-domain remains attached to the A3-domain. 
Cleavages at both Arg709 and Arg1018 release a 71,000 kDa-peptide fragment of the B-
domain. The remaining part of the B-domain (150,000 kDa) is released upon cleavage 
at Arg1545.  
 
 
 
 
 
 11
activity.  Previous data have demonstrated that factor VaNN results in an active factor 
Va molecule that has an amino acid segment missing from the heavy chain 
representing a binding site for prothrombin (amino acids 697-709) (22). 
1.5.2 Factor V Post-translational Modification 
     The Factor V molecule undergoes several post-translation modifications, including 
sulfation, phosphorylation, and glycosylation (Figure 1.3).  It has been demonstrated 
that sulfation is important for factor Va function (23).  Factor Va is phosphorylated at 
amino acid residue Ser692 by a membrane associated platelet casein kinase II (CKII); 
phosphorylation at this residue increases the inactivation rate of the cofactor by APC 
(24).  The Factor Va molecule is phosphorylated at two positions on the light chain by 
a platelet derived protein kinase C isoform (25, 26).  Factor V has several possible N-
linked glycosylation sites located on the B region and on the heavy and light chains 
that aid in secretion of the molecule (16).  Additionally, several other blood-clotting 
factors go through a post-translational modifications of glutamic acid to γ-
carboxyglutamic acid by a vitamin K-dependent carboxylase.  The γ-carboxyglutamic 
acid residues of the vitamin K-dependent blood clotting proteins are located at the N-
terminal “Gla-domain”; these proteins include prothrombin, protein C, protein S, 
factor VII, factor IX, and factor X.  The Gla-domain is responsible for the membrane-
dependent binding of the proteins (27). 
1.6 Factor Va binding to factor Xa 
    Establishment of the factor Xa-factor Va complex involves three steps: 1) binding 
of factor Xa a to negatively charged membrane surface, 2) binding of factor Va to the 
same membrane surface, and 3) diffusion of the membrane bound proteins leading to  
 12
 
 
 
 
Figure 1.3: Human Factor V.  Shown above is an illustration of the human factor V 
molecule.  The top arrows indicate activation cleavage sites by thrombin, factor Xa, 
and RVV-V activator.  The bottom arrows show the inactivation cleavages by APC 
and plasmin.  The posttranslational modification sites are also indicated.  (Taken from 
Mann and Kalafatis, 2003). 
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the association of the proteins (28).  Factor Xa and factor Va can interact in the 
absence of a membrane surface with a Kd of 0.8µM and it’s interaction is dependent 
upon calcium ions (29).   However, in the presence of a membrane surface and Ca2+, 
the interaction of factor Xa and factor Va has a Kd of ~1nM (30). It has also been 
recognized that both chains of factor Va are required for the interaction with factor 
Xa (31-34).  It has been further demonstrated that it is the A1 and A3 domains that 
are involved in this interaction (34).  Factor V also binds to the membrane’s surface 
to help stabilize this interaction through the C2 and A3 domains of the molecule 
located on the light chain.  It has been established that this interaction is governed by 
both electrostatic and hydrophobic interactions with the membranes (35-39)  Recent 
kinetic data have shown that the binding of factor Va to factor Xa exposes exosites on 
the enzyme remote from the active site (40).  It allows for more specific interaction 
with the substrate, prothrombin (41). 
1.7 Factor Va binding to prothrombin and/or thrombin  
     The primary structure of factor Va lends to the ability of the COOH-terminus of 
the heavy chain to play a role in protein-protein interactions.  This region of the 
cofactor molecule is highly acidic and should be expected to be on the surface of the 
molecule making it readily available for protein-protein interactions (42).  Further, 
this region also contains tyrosine residues and hirudin-like motifs that have been 
previously shown to be involved with activation of the pro-cofactor, factor V, as well 
as cofactor function (23, 43).  Hirudin is a naturally occurring peptide in the salivary 
glands of medicinal leaches.  This peptide has anticoagulant activity through it’s 
ability to specifically inhibit thrombin activity (44).  It has been demonstrated that 
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factor Va interacts with the substrate, prothrombin, via the heavy chain of the 
molecule (30, 32).  Furthermore, a synthetic peptide, amino acid residues 697-709 
from the COOH-terminus of the heavy chain of factor Va, was found to interact 
directly with thrombin agarose, indicating these residues of the cofactor provide a 
binding site for thrombin and/or prothrombin (45). 
1.8 Down Regulation of the Coagulation Cascade 
     Once enough thrombin is produced to stop bleeding by the formation of the fibrin 
clot, it then has the ability to participate in the down regulation of the coagulation 
cascade.  Thrombin, therefore, has a dual effect on the cascade; it possesses both 
coagulant and anti-coagulant properties.  When the cofactor thrombomodulin (TM) 
binds to thrombin, it switches its role form pro-coagulant to anti-coagulant.  Now this 
IIa/TM complex can start the down-regulation of the blood coagulation cascade by 
activating Protein C (PC) to its active form, Activated Protein C (APC); IIa/TM is the 
enzymatic complex capable of this activation. 
1.8.1 Thrombin/Thrombomodulin Activation of Protein C 
     Thrombomodulin is an endothelial cell surface glycoprotein cofactor that is 
composed of 559 amino acids and contains five domains: an NH2-terminal domain 
(residues 1-224), six Epidermal Growth Factor (EGF)-like domains (residues 225-
461), a 34 amino acid portion that includes eight hydroxyamino acids, a hydrophobic 
membrane-spanning domain (residues 497-520), and a cytoplasmic tail domain 
(residues 521-559) (46).  Protein C (PC) is a vitamin K-dependent serine protease 
zymogen that circulates in plasma at a concentration of 60nM.  PC is composed of a 
heavy chain and light chain with Mr of 41,000 and 21,000, respectively.  The chains 
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are connected through a disulfide bond (47).  For the activation of Protein C, the 
enzyme, IIa, and the substrate, PC, need the function of a cofactor for the reaction to 
work in a physiological efficient manner.  For PC, the cofactor is Ca2+.  It has been 
demonstrated that Ca2+ binds to the 70-80 loop of the protease domain on the 
zymogen form of PC (48).  Upon activation, PC is converted to its active form, APC, 
by cleavage at Arg169 of the heavy chain by the IIa/TM complex in the presence of 
Ca2+ (47).   
1.8.2 Activated Protein C Inactivation of Coagulation Cofactors 
     Once activated, APC down regulates the coagulation cascade by inactivating the 
protein cofactor, factor Va, by sequential proteolysis (49, 50).  Another vitamin K-
dependent, Gla-domain containing protein, Protein S, serves as a cofactor to APC (51, 
52).  The cofactor function of protein S is weak in purified systems, only enhancing 
the APC inactivation of factor Va by a factor of two (53).  APC inactivates factor Va 
following proteolytic cleavages at Arg306, Arg506, and Arg679 (Figure 1.4).  It has been 
shown that proteolytic cleavage at Arg506/Arg679 results in a factor Va molecule with 
a 10-fold decrease in its affinity for factor Xa.  These same cleavages results in the 
elimination of its interaction with prothrombin.  APC can also inactivate the pro-
cofactor, factor V.  APC cleaves the pro-cofactor in the presence of a membrane 
surface at residues Arg306, Arg506, Arg679, and Lys994.  It is the first cleavage at Arg306 
that is the inactivating cleavage of the procofactor (54).  In addition, APC also can 
inactivate factor VIIIa; however, APC cleavage does not appear to be essential to 
inactivation because factor VIIIa inactivation occurs spontaneously following the 
dissociation of the A2 domain (55-57). 
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1.8.3 Factor VLEIDEN 
     The importance of cofactors to the blood coagulation cascade is specifically 
portrayed by the clinical consequences of mutations to factor V/Va.  One of the most 
prevalent mutations, occurring in 5% of the normal population in Western Countries, 
is the factor VLEIDEN mutation.  It was discovered in 1993 by Dahlback et al. when 
they observed that plasma from several individuals has a slower response to APC 
inactivation (58).  Factor VLEIDEN is a result of a single point mutation at amino acid 
residue 1691 of G → A, resulting in a factor V molecule with an Arg506 → Gln 
substitution (59).  Arg506 is the initial cleavage site for APC on the heavy chain of 
human factor Va and makes possible the following lipid-dependent inactivation 
cleavage at Arg306.  This amino acid replacement results in a cofactor that is unable to 
be cleaved at residue 506 by APC.  The  resistance of factor VLEIDEN to APC 
inactivation has been shown to be a major risk for venous thrombosis (60).  
Individuals homozygous for this mutation have an 80-fold higher risk for thrombosis 
than individuals that possess the normal factor V gene, and individuals that are 
heterozygous for factor VLEIDEN have a 7-fold higher risk for thrombosis than healthy 
individuals.  The inability of factor VLEIDEN to be cleaved at residue 506 results in a 
slower rate of cleavage at Arg306 and Arg679 by APC compared to normal plasma 
factor Va.  The slower rate of cleavage has been shown to be a result of the delayed 
cleavage at Arg506, suggesting that the cleavage at Arg506 is necessary for the efficient 
inactivation of the cofactor, factor Va, by APC (61). 
 
 
 17
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Diagram of Factor Va Inactivation by APC.  APC inactivates factor 
Va by 3 proteolytic cleavages.  First at Arg506, followed by cleavage at Arg306 and 
Arg679.  These cleavages lead to an inactive cofactor. 
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1.8.4 Factor V Cambridge and Factor V Hong Kong 
     In 1998, two new mutations in factor V were discovered, factor V Hong Kong 
(factor VHG) and factor V Cambridge (factor VCAM) (62, 63).  Both mutations result in 
the substitution of amino acid residue 306, Gly for FVHG and Thr for FVCAM.  It was 
suspected that a mutation at Arg306 would cause a severe thrombotic state, since it is 
cleavage at Arg306 in factor Va by APC that causes complete inactivation of the 
cofactor.  On the contrary, preliminary evidence has shown that neither factor VHG 
nor factor VCAM appears to be correlated with an increased risk for thrombosis (64, 
65).  Additional evidence is needed to further elucidate the mechanism of these 
mutations in factor V. 
1.9 Prothrombin  
     Prothrombin is composed of five domains: an N-terminal γ-carboxyglutamic acid 
(Gla) domain, an aromatic amino acid stack domain, two kringle domains, and a C-
terminal serine protease domain (Figure 1.5).  It has been demonstrated that the Gla 
domain, which contains ten γ-carboxyl-glutamic acid residues, is responsible for its 
calcium binding properties (66, 67).  The Gla domain is also responsible for binding 
of most vitamin K-dependent proteins to the phospholipid membrane surface.  It has 
shown that prothrombin and thrombin contain two electropositive exosites, anion 
binding exosite I (ABE-I) and anion binding exosite II (ABE-II).  They are 
responsible for the functions of these molecules.  Studies have shown that ABE-I 
binds to thrombomodulin (68), fibrinogen (69), PAR1 (70), the COOH-terminal of 
hirudin peptides (71), and heparin cofactor II (72).  ABE-II interacts with the protease  
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Figure 1.5: Schematic of Prothrombin activation.  Prothrombin is composed of ten 
γ-carboxyglutamic residues (hatched), two kringle domains (checkered), and a serine 
protease domain (black). Pathway I shows cleavage by the factor Xa and a membrane 
surface.  Pathway II shows cleavage by the prothrombinase complex (Taken from 
Bukys et al. 2006). 
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nexin (73).  Both exosites have been shown to bind factor V and factor VIII (74).  It 
has also been demonstrated that pro-exosite I of the zymogen, prothrombin, interacts 
directly with factor Va in the prothrombinase complex (75, 76). 
1.9.1 Prothrombin Activation by Prothrombinase 
     The activation of prothrombin can occur through two pathways.  In Pathway I, 
which the enzyme alone activates prothrombin, following first cleavage at Arg271 
giving Fragment 1.2 and Prethrombin-2 as intermediates (Figure 1.3).  The second 
proteolytic cleavage at Arg320 produces the active thrombin molecule and Fragment 
1.2.  (77-79).  Overall, this reaction is slow and is not compatible with survival.  In 
Pathway II, incorporation of the cofactor, factor Va, into the prothrombinase complex 
reverses the order of these proteolytic cleavages.   It cleaves first at Arg320 to produce 
an active intermediate, Meizothrombin, and it cleaves secondly at Arg271 to give 
thrombin and Fragment 1.2.  Thus, the incorporation of the cofactor, factor Va, into 
the prothrombinase complex increases the catalytic efficiency of the enzyme alone by 
five orders of magnitude (80, 81).  The high increase in the turnover number is due to 
two things: (1) an 100-fold decrease in the Km as a result of the interaction with the 
membrane surface localizing the concentration of the substrate and (2) a 3,000-fold 
increase in the kcat of the enzyme as the result of the incorporation of factor Va into 
the prothrombinase complex (82, 83).  
1.10 New Evidence of Two Equilibrating Forms of Prothrombinase 
     There have been many studies investigating the mechanism by which coagulation 
factor Va enhances the rate of prothrombin activation.  It has been demonstrated that 
prothrombin interacts with prothrombinase at exosites that are located at a spatially 
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distinct site from the active site of factor Xa and that these exosites on prothrombin 
may perhaps arbitrate substrate recognition and cleavage (75, 84).  Obtained data 
have also illustrated that it is the heavy chain of factor Va that interacts with the 
fragment-2 domain of the substrate prothrombin (84-86).  Recent data have shown 
that an interaction exists between factor Va and proexosite I of prothrombin (76).  
Additionally, x-ray crystallographic evidence of prothrombin-2 has shown that the 
residues preceding the cleavage site at Arg320 must go through massive rearrangement 
in order to properly dock in the active site of factor Xa (87).  New research has 
demonstrated that the ordered steps of prothrombinase on the two activating 
cleavages in prothrombin occurs from the hindering effects of the substrate bound in 
two separate conformations through comparable exosite binding interactions to a 
single form of prothrombinase (88).  This group has also provided evidence that 
ratcheting of the substrate, prothrombin, from the inactive zymogen conformation to 
the active proteinase conformation forces the ordered presentation of the two 
cleavage sites at Arg271 and Arg320 to the active site of the enzyme leading to the 
sequential activation cleavages on prothrombin by prothrombinase (89).  However, 
another group has proposed a mechanism that shows there are two equilibrating forms 
of prothrombinase involved in prothrombin activation; the model depicts two forms 
of the enzyme each recognizing one of the prothrombin cleavage sites.  The authors 
concluded that the kinetics of prothrombin activation follow a “ping-pong”-like 
mechanism (81).  Further research needs to be performed to resolve the exact 
mechanism of prothrombin activation by the prothrombinase complex. 
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CHAPTER II 
THE ESSENTIAL CONTRIBUTION OF ASP334 AND TYR335 FROM 
FACTOR Va HEAVY CHAIN TO THE CATALYTIC EFFICIENCY OF 
PROTHROMBINASE 
 
 
2.1 Abstract 
     Incorporation of factor Va into prothrombinase results in a 300,000-fold 
acceleration of the catalytic efficiency of prothrombinase as compared to the reaction 
catalyzed by factor Xa alone. We have demonstrated that amino acids E323, Y324, E330, 
and V331 from factor Va heavy chain are crucial for the binding of factor Xa and are 
required for coordinating the spatial arrangement of enzyme and substrate directing 
prothrombin cleavage.  We have also demonstrated that amino acid region 332-336 
contains residues that are involved in cofactor function.  In the present study using 
overlapping peptides from this region we have identified amino acid residues 
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334DY335 as important contributors for factor Va cofactor activity.  Site-directed 
mutagenesis was used to study the effect of these amino acids on the catalytic 
efficiency of prothrombinase.  We have constructed recombinant factor V molecules 
with the mutations D334→K and Y335→F (factor VKF) and D334→A and Y335→A 
(factor VAA).  These molecules was transiently expressed and purified to 
homogeneity.  Kinetic studies showed that while factor VaKF and factor VaAA had a 
KD for factor Xa similar to the KD observed for wild type factor Va, the clotting 
activity of the mutant molecules was significantly impaired and the kcat of 
prothrombinase assembled with factor VaKF and factor VaAA was notably reduced.  
The second order rate constant of prothrombinase assembled with factor VaKF and 
factor VaAA , for prothrombin activation, was 8-fold and 12-fold lower, respectively, 
than the second order rate constant for the same reaction catalyzed by prothrombinase 
assembled with the wild type molecule.  We have also created two quadruple 
mutants, factor VFF/KF (E323F/Y324F and D334K/Y335F), factor VMI/KF 
(E330M/V331I and D334K/Y335F), factor VFF/AA (E323F/Y324F and 
D334A/Y335A), and factor VMI/AA (E330M/V331I and D334A/Y335A).  
Prothrombinase assembled with factor VaFF/KF showed a 47-fold decrease in the 
second order rate constant while under similar experimental conditions 
prothrombinase assembled with factor VaMI/KF had a 400-fold decrease in the second 
order rate constant.  The quadruple mutants containing the D334A/Y335A mutations 
also has decreased second order rate constants, factor VaFF/AA and factor VaMI/AA had 
16-fold and 27-fold decreased values, respectively.  Time courses studying 
prothrombin activation by gel electrophoresis demonstrated that prothrombinase 
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assembled with all these mutants had reduced rates for prothrombin activation.  The 
data demonstrate that amino acid 334-335 from factor Va do not participate in the 
interaction with factor Xa but are rather required for the rearrangement of enzyme 
and substrate necessary for efficient catalysis. 
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2.2 Introduction.   
     The mainstay of the hemostasis process is the generation of thrombin, which in 
turn promotes the assembly of the fibrin plug following vascular injury.  The 
prothrombinase complex is composed of the enzyme, factor Xa, and the protein 
cofactor, factor Va, associated in the presence of divalent metal ions on a membrane 
surface (1, 2).  This complex catalyzes the activation of prothrombin to its active 
form, thrombin.  Prothrombin circulates in blood as an inactive zymogen (Mr = 
72,000) at a physiological concentration of 1.4µM.  The enzyme, factor Xa, alone can 
activate prothrombin by two sequential proteolytic cleavages at Arg271 and Arg320 
resulting in the intermediates, fragment 1•2 and prethrombin 2 (3, 4).  The overall rate 
of this reaction is not compatible with survival.  On the other hand, the incorporation 
on the cofactor, factor Va, into prothrombinase reverses the order of the proteolytic 
cleavages and increases the catalytic activity of factor Xa by 5 orders of magnitude 
(5).  The first cleavage at Arg320, which is strictly dependent on the incorporation of 
factor Va into prothrombinase, produces the intermediate meizothrombin, which has 
reduced clotting activity compared to thrombin, but it has normal amidolytic activity.  
Further cleavage at Arg271 generates thrombin and fragment 1•2 (6, 7).  The 
regulation of this key step in the blood coagulation cascade has been under intense 
investigation for many years. 
     Plasma factor V circulates as an inactive protein cofactor of Mr 330,000(8).  The 
inactive zymogen protein cofactor, factor V, cannot participate in the prothrombinase 
complex and aid in prothrombin activation.  Factor V must first be activated to factor 
Va by thrombin through 3 sequential proteolytic cleavages at Arg709, Arg1018, and 
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Arg1545 to produce a heavy chain, composed of amino acid residues 1-709 (Mr 
105,000) and a light chain composed of amino acid residues 1546-2196 (Mr 74,000) 
(3).  Both chains of factor Va have been shown to be required for interaction of the 
cofactor with factor Xa (9, 10).  While the binding site(s) on the light chain remain to 
be identified, several binding sites for factor Xa on the factor Va heavy chain have 
been delineated.  Griffin et al. have demonstrated that binding sites for factor Xa on 
factor Va are located within amino acid residues 311-325 (11) and 493-506 (12).   
Using synthetic peptides we have demonstrated that amino acid region 323-331 of the 
factor Va heavy chain contain critical amino acid residues responsible for the direct 
interaction of the cofactor with factor Xa (13).  Our laboratory’s initial results also 
demonstrated that amino acid sequence 332IWDYA336, which is continuous to the 
factor Xa binding site, was also involved in the inhibition of prothrombinase activity.  
The present study was undertaken to understand the precise contribution of amino 
acid residues 332-336 of the factor Va heavy chain to the catalytic efficiency of 
prothrombinase. 
     After sufficient thrombin production for the formation of the fibrin clot, 
inactivation of the coagulation cascade commences.  Factor Va is inactivated by APC 
in the presence of a membrane surface by three sequential cleavages at Arg306, Arg506, 
and Arg679 resulting in the dissociation of the A2 domain from the rest of the 
molecule (14, 15).  Factor Va can also be inactivated by plasmin in the presence of a 
membrane surface.  Plasmin is a serine protease with a broad range of substrates.  In 
addition to the cleavage of fibrin, it also is capable of activation or inactivation of 
blood coagulation proteins.  Plasmin cleaves factor Va at Lys309, Lys310, Arg313, and 
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Arg348 which also results in the dissociation of the A2 domain of factor Va (Figure 4) 
(16).  Further analysis of the inactivation fragments of factor Va by plasmin 
demonstrated that amino acid residues 307-348 are critical for factor Va cofactor 
function.  Specifically, a peptide spanning this amino acid region is a good inhibitor 
of factor V/Va clotting activity (16).  Additionally, this region of factor Va is also 
thought to be important for cofactor function since it is 82% conserved between 
human (17), bovine (18), mouse (19), and porcine (20).   
     To further understand the importance of amino acid region 307-348 of the factor 
Va heavy chain, eight overlapping peptides (designated AP1-AP8) were synthesized 
and characterized for inhibition of prothrombinase activity (Figure 2.1) (13).  Studies 
showed that peptide AP4’, containing amino acid residues 323-331, is partially 
responsible for the interaction of factor Xa with factor Va.  Accordingly, this peptide 
was studied extensively and it was determined that within these nine amino acids, 
some or all the residues are critical for the interaction of factor Va heavy chain with 
factor Xa in the prothrombinase complex.   Furthermore, these residues are necessary 
for factor Va cofactor function (13).  In addition, analysis of the peptides also 
revealed that under the experimental conditions employed (4nM factor Va and 10nM 
factor Xa pre-incubated with 100µM peptides), peptides AP3-AP6 were all found to 
inhibit prothrombinase activity (13).  Particularly, it was found that amino acid region 
332IWDYA336 might contribute to the inhibitory potential of prothrombinase activity.  
These studies lead to the hypothesis that a small amino acid region of factor Va heavy 
chain is enough to interact with factor Xa and increase its ability to activate 
prothrombin in the absence of the whole cofactor.  This region includes amino acid 
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region 332IWDYA336.  In addition to kinetic data obtained with the peptides, structural 
analysis of factor Va has been performed.  It was found that the amino acid residues 
under investigation are located on the surface of the molecule (13). 
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Figure 2.1 Peptides From the Central Portion of Factor Va Heavy Chain.  We 
have recently demonstrated that amino acid region 307-348 of factor Va heavy chain 
is critical for cofactor function.  This region was broken down into 8 overlapping 
peptides.  Kinetic analysis revealed that amino acid region 323-331, designated AP4’ 
is a noncompetitive inhibitor of prothrombinase with respect to thrombin.  Thus, the 
peptide interferes with the Va-Xa interaction.  In other words, AP4’ contains a 
binding site for factor Xa on the heavy chain of the cofactor. In addition, amino acid 
region 317-326, designated as AP3, was found to be a non-competitive inhibitor of 
prothrombinase with respect to thrombin. (Figure taken from: Kalafatis, M and Beck, D.O. (2002) 
Biochemistry 41, 12715-12728.) 
 
 
 
 
 
 
 
 
 
         N307LKKITREQRRH MKRWEYFIAAEEVIWDYAPVIPANMDKKYRSQH351 
         
AP1     NLKKITREQR 
AP2                  TREQRRHMKR 
AP3                           RHMKRWEYFI 
AP4’                               WEYFIAAEEV 
AP5                                            AAEEVIWDYA 
AP6                                               IWDYAPVIPA 
AP7                                                             PVIPANMDKK 
AP8                                                             NMDKKYRSQH 
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2.3 Experimental Procedures  
2.3.1 Materials and Reagents 
     Diisopropyl-fluorophosphate (DFP), O-phenylenediamine (OPD)-dihydrochloride, 
N- [2-Hydroxyethyl] piperazine-N’-2-ethanesufonic acid (Hepes), Trizma (Tris base), 
and Coomassie Blue R-250, were purchased from Sigma (St. Louis, MO).  Factor V-
deficient plasma was from Research Protein Inc. (Essex Junction, VT).  Secondary 
anti-mouse and anti-sheep IgG coupled to peroxidase were purchased from Southern 
Biotechnology Associates Inc. (Birmingham, AL).  L-α-phosphatidylserine (PS) and 
L-α-phosphatidylcholine (PC) were from Avanti Polar Lipids (Alabaster, AL).  
Chemiluminescent reagent ECL+ and Heparin –Sepharose were from 
AmershamPharmacia Biotech Inc. (Piscataway, NJ).  Normal reference plasma and 
chromogenic substrate Spectrozyme-TH were from American Diagnostica Inc. 
(Greenwich, CT).  Thromboplastin reagent was purchased from Organon Teknika 
Corp.  (Durham, NC).  EDC (1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide 
Hydrochloride) was from Pierce Biotechnology (Rockford, IL).  Dansylarginine-N-
(3-ethyl-1, 5-pentanediyl) amide (DAPA), human factor Xa, human thrombin, and 
human prothrombin was purchased from Haematologic Technologies Inc. (Essex 
Junction, VT).  Factor V cDNA was from American Type Tissue Collection (ATCC# 
40515 pMT2-V, Manassas, VA).  All restriction enzymes were from New England 
Biolabs (Beverly, MA).  All molecular biology and tissue culture reagents, specific 
primers, and medium were from Gibco, Invitrogen Corp. (Grand Island, NY) or as 
indicated.  Human factor V monoclonal antibodies (αHFVHC#17 and αHFVLC#9) and 
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monoclonal antibody αHFV#1 coupled to Sepharose were provided by Dr. Kenneth 
G. Mann (Department of Biochemistry, University of Vermont, Burlington, VT). 
2.3.2 EDC Cross-linking of Heavy Chain Peptides 
     To investigate if peptides from factor Va heavy chain, N42R, AP3, AP5, AP6, and 
IWDYA interact with factor Xa, chemical cross-linking with EDC (1-Ethyl-3-(3-
Dimethylaminopropyl)carbodiimide Hydrochloride) was used.  Factor Xa with the 
active site blocked, FXa-EGR, was incubated by itself or with a 25 molar excess of 
each peptide, in the presence of lipids and the chemical cross-linker, EDC, for two 
hours at ambient temperature (370C).  The protein was then separated by reducing 
SDS-PAGE, followed by staining with Coomassie Blue to visualize the heavy chain 
(Mr = 42,000) and the light chain (Mr = 16,5000) of factor Xa. 
2.3.3 Inhibition by Factor Va Heavy Chain Peptides 
     The ability of the heavy chain peptides to inhibit prothrombinase function in the 
absence of factor Va was investigated in an assay with purified reagents.  The 
peptides, P15H, AP5, AP5m, and IWDYA, were pre-incubated with factor Xa.  The 
reaction mixture containing prothrombin (350nM), DAPA (750nM), and PCPS 
(10µM) was incubated in the dark for 20min, prior to the start of assays.  At selected 
time intervals, an aliquot (1800µL) of the reaction mixture was added to the cuvette 
and the baseline was monitored on a Perkin-Elmer LS-50B Luminescence 
Spectrometer with λex = 280nm, λem = 550nm, and a 500nm long-pass filter in the 
emission beam.  The data obtained were immediately analyzed with the software FL 
WinLab.  The reaction was started upon the addition of factor Xa plus peptide 
(concentrations ranging from 0-500µM) to a final concentration of 10nM factor Xa.  
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The fluorescence intensity due to the formation of thrombin from activation of 
prothrombn and its complexation with  DAPA was monitored with time.  The results 
were plotted as % cofactor activity versus peptide concentration. 
2.3.4 Prothrombin Activation by Heavy Chain Peptides Analyzed by Gel 
Electrophoresis 
     Peptides from the heavy chain of factor Va were assessed for their ability to 
activate prothrombin in the absence of factor Va.  Plasma factor Va and the peptides, 
50µM N42R, 100µM P15H, 100µM AP3, 100µM AP5, 100µM AP5m, 100µM AP6, 
100µM IWDYA and factor Xa alone were pre-incubated with 1nM factor Xa, 20µM 
PCPS, and 3µM DAPA in TBS, Ca2+, pH 7.40 for 5 minutes at room temperature.  A 
zero point was taken and 1.4µM prothrombin was added to start the reaction.  
Aliquots were removed at the following time points, 0.5, 1, 3, 5, 7, 10, 12, 15, 20, 30, 
45, 60, 75, 90, 105, 120, 150, 180 diluted in two volumes of 0.2M glacial acetic acid.  
In order to compare prothrombin activation between the different peptides and plasma 
factor Va, time points were taken at the following times, 3min and 30min for plasma 
factor Va, and one hour for the peptides and factor Xa alone and diluted in two 
volumes of 0.2M glacial acetic acid.  The samples were dried in a centrivap and 
reconstituted in 0.1M Tris base, pH 6.8, 1% SDS, 1% β-mercaptoethanol and heated 
for exactly 75 seconds at 950C.  A total of 5µg of total protein was loaded per lane 
and analyzed by SDS-PAGE with a 9.5% acrylamide gel followed by staining with 
Coomassie Blue. 
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  2.3.5 Construction of Recombinant Factor V Molecules 
     Recombinant factor VMI and factor VFF molecules (having the mutations 323-324 
(E323F, Y324F) and 330-331 (E330M, V331I)) were constructed in a two-stage PCR 
method and characterized as previously described (21).  Factor VKF was obtained in 
the same manner; briefly, factor VKF was constructed using the mutagenic primers, 5’-
C ATT TGG AAG TTT GCA CCT G-3’ (forward) and 5’-C AGG TGC AAA CTT 
CCA AAT G-3’ (reverse)  (bold underlined letters identify the mutated bases).  The 
resulting amplicon was sub cloned into the vector pGEM-T.   The PGEM-T plasmid 
was digested with restriction enzymes; Bsu361 and Xcm1, to remove the factor V 
insert and the insert was ligated into pMT2-FV at the same restriction sites.  The 
remaining recombinant plasmids were constructed using Stratagene’s QuikChange® 
XL Site-Directed Mutagenesis Kit.  Factor VAA was constructed with the primers 5’-
GAG GAA GTC ATT TGG GCC GCC GCA CCT GTA ATA- 3’ (forward) and 5’-
TAT TAC AGG TGC GGC GGC CCA AAT GAC TTC CTC-3’ (reverse).  Factor 
VMI/KF was constructed with the primers 5’- GAA TAC TTC ATT GCT GCA GAG 
ATG GTC ATT TGG AAG TTT GCA CCT GTA ATA-3’ (forward) and 5’-TAT 
TAC AGG TGC AAA CTT CCA AAT GAC CAT CTC TGC AGC AAT GAA 
GTA TTC-3’ (reverse).  Factor VFF/KF was constructed with the primers 5’-CAC ATG 
AAG ATT TGG TTT TTC TTC ATT GCT GCA GAG GAA GTC ATT TGG AAG 
TTT GCA CCT GTA ATA-3’ (forward) and 5’-TAT TAC AGG TGC AAA CTT 
CCA AAT GAC TTC CTC TGC AGC AAT GAA GAA AAA CCA AAT CTT CAT 
GTG-3’ (reverse).  Factor VMI/AA was constructed with the primers 5’- GAA TAC 
TTC ATT GCT GCA GAG ATG GTC ATT TGG GCC GCC GCA CCT GTA 
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ATA-3’ (forward) and 5’-TAT TAC AGG TGC GGC GGC CCA AAT GAC CAT 
CTC TGC AGC AAT GAA GTA TTC-3’ (reverse).   Factor VFF/AA was constructed 
with the primers 5’-CAC ATG AAG ATT TGG TTT TTC TTC ATT GCT GCA 
GAG GAA GTC ATT TGG GCC GCC GCA CCT GTA ATA-3’ (forward) and 5’-
TAT TAC AGG TGC AAA CTT CCA AAT GAC TTC CTC TGC AGC AAT GAA 
GAC CAT CCA AAT CTT CAT GTG-3’ (reverse).   Factor VI332A was constructed 
with the primers 5’-GCT GCA GAG GAA GTC GCT TGG GAC TAT GCA CCT 
GTA ATA-3’ (forward) and 5’-TAT TAC AGG TGC ATA GTC CCA AGC GAC 
TTC CTC TGC AGC-3’ (reverse).  Factor VW333A was constructed with the primers 
5’-GCT GCA GAG GAA GTC ATT GCG GAC TAT GCA CCT GTA ATA-3’ 
(forward) and 5’-TAT TAC AGG TGC ATA GTC CGC AAT GAC TTC CTC TGC 
AGC-3’ (reverse).  The Scheme of the recombinant factor V molecules is shown in 
Figure 2.2.  The mutations were confirmed by DNA sequencing (DNA Analysis 
Facility, Cleveland State University).   
2.3.6 Transient Transfection of Recombinant Factor V Molecules 
     The COS-7L cell line was maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum and the antibiotics streptomycin 
(100µg/ml) and penicillin (100IU/ml) in an atmosphere of 5% CO2, 95% air, and 
370C.  The purified wild type and mutated plasmids will be transfected into the COS-
7L cells with fugene 6 (Roche Diagnostics) according to the manufacturer’s 
instructions.  After 48 hours of incubation, the cells were washed twice with PBS 
buffer and 6ml of VP-SPM medium supplemented with 4mM L-glutamine will be 
added.  Following 24 hours the medium was harvested and fresh VP-SPM medium 
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was added.  Harvesting of protein was repeated for 3-4 consecutive days and the 
harvest medium was stored at -800C.  The    harvest medium was concentrated using a 
Cole Parmer, Masterflex L/S with MW=30,000 Vivaflow 50 membrane to a volume 
of 5-15mLs.  Then, 2mM DFP was added and the protein was allowed to sit ice for 
half an hour to overnight before purifying the recombinant protein. 
2.3.7 Purification of Recombinant Factor V Molecules 
     The concentrated recombinant protein was centrifuged at 5,000 rpm for 5 minutes 
to remove any cellular debris.  The protein was purified on a 2ml column of 
monoclonal antibody αhFV#1 coupled to sepharose.  The column was first 
equilibrated with TBS plus 5mM Ca2+, pH 7.40 (TBS, Ca2+) (all buffers were filtered 
before use).  The medium containing recombinant protein  was added to the column 
and 0.5ml fractions were collected.  The column was washed with 12ml of TBS, Ca2+ 
and eluted with 20mM Tris Base, 2M NH3Cl, pH 7.40.  The absorbance of the 
collected fractions was recorded at 280 nm on a HITACHI U-2000 spectrophotometer 
and clotting activity monitored cofactor activity.  Fractions containing activity were 
pooled and dialyzed against TBS, Ca2+, pH 7.40 for 2 hours at 40C.  The purified 
protein was stored at -800C in small aliquots to avoid repeated freeze thaw cycles.  
The activity and the integrity of the recombinant factor V molecules were confirmed 
by clotting assays using factor V deficient plasma and western blotting with 
monoclonal and polyclonal antibodies. 
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Figure 2.2 Schematic of recombinant factor V molecules from the central 
portion of the heavy chain.  Model of factor V gene depicting the residues that have 
been mutated, E323, Y324, E330, V331, D334, Y335, I332, and W333. 
 
 
 
 
 
 
 
 
 
Recombinant Factor V Molecules 
Factor VWT   No Mutation 
Factor VKF   D334 → K, Y335 → F 
Factor VAA   D334 → A, Y335 → A 
Factor VFF/KF   E323 → F, Y324 → F, D334 → K, Y335 → F 
Factor VFF/AA   E323 → F, Y324 → F, D334 → A, Y335 → A 
Factor VMI/KF   E330 → M, V331 → I, D334 → K, Y335 → F 
Factor VMI/AA   E330 → M, V331 → I, D334 → K, Y335 → F 
Factor VI332A   I332 → A 
Factor VW333A  W333 → A 
307NLKKITREQRRH MKRWEYFIAAEEVIWDYAPVIPANMDKKYRSQH351
A C C COOA A
Arg709 Arg1545Arg1018
B 
FF MI KF or AA
A A
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2.3.8 Determination of Factor Va Clotting Activity of the Recombinant 
Molecules 
     The cofactor activity of the recombinant molecules was measured in a clotting 
assay using factor V-deficient plasma following activation of the cofactor molecules 
by thrombin (10min, 37ºC).  The values were measured on a ST art 4 Analyzer 
Coagulation Instrument (Diagnostica Stago, Parisippany, NJ) and the values were 
standardized to the percentage of control.  A linear semi-log graph was created using 
known concentrations of plasma factor Va as a control and the specific activity of 
each recombinant factor Va molecule was calculated (units/mg). 
2.3.9 Gel Electrophoresis and Western Blotting 
     Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analyses 
were carried out using 4-12% gradient gels or 9.5% gels following reduction with 2% 
β-mercaptoethanol according to the methods of Laemmli (1970).  The protein was 
transferred to polyvinylidene difluoride (PVDF) membranes following the described 
method of Towbin et al. (1979).  Factor Va heavy and light chains were probed with 
the appropriate antibodies and visualized with chemiluminescence; or, the protein 
was visualized by staining with Coomassie Brilliant Blue R-250, followed by 
destaining in a solution of methanol, acetic acid, and water. 
2.3.10 Factor Va Titrations 
     The ability of the recombinant factor V molecules to assemble in the 
prothrombinase complex and bind to the enzyme was measured in a discontinuous 
assay described in detail elsewhere (22).  In short, all recombinant factor V molecules 
were activated with thrombin (10 min. at 370C).  Reaction mixtures contained PCPS 
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vesicles (20µM), DAPA (3µM), factor Xa (varying concentration), and recombinant 
factor V species in Reaction Buffer (varying concentration) HEPES, 0.15M NaCl, 
50nM CaCl2, 0.01% Tween-20, pH 7.40).  For the practical calculation of the kd 
between the factor Va molecules and factor Xa, assays were performed in the 
presence of limiting factor Xa concentration (15pM) and varying concentrations of 
the recombinant factor Va species (25pM to 5nM).  A zero point was taken and the 
reaction was started upon the addition of 1.4µM prothrombin.  At the following time 
points 10, 20, 30, and 60 seconds, aliquots of the reaction mixture were removed and 
diluted in 2 volumes quench solution (20nM HEPES, 0.15M NaCl, 50nM EDTA, 
0.1% PEG 8000, pH 7.40) in a 96-well sample plate.  The rate of thrombin generation 
was measured using a chromogenic substrate, Spectrozyme TH (0.4nM), which 
probes for thrombin generation.  The initial rate of thrombin generation was analyzed 
with Prizm (GraphPad) software. 
2.3.11 Prothrombin Titrations 
     The capability of the recombinant factor Va molecules to assemble into the 
prothrombinase complex, binding to the substrate prothrombin, and the rate of 
catalytic efficiency was measured.  For the determination of the kinetic constants of 
prothrombinase assembly, Km and kcat, experiments were executed with a limiting 
amount of factor Xa (5pM) in the presence of a fixed amount of the various 
recombinant factor Va molecules (10nM), PCPS vesicles (20µM), and DAPA (3µM) 
in Reaction Buffer.  In order to compensate for the variation in the kd between the 
different recombinant molecules, the amount of factor Va needed to saturate factor 
Xa was calculated as described below. A zero point was taken and the reaction was 
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started with varying amounts of the substrate prothrombin (25nM to 4µM).  Aliquots 
were removed at the time points 20, 40, 60, and 120 seconds and the reaction was 
stopped in 2 volumes Quench Buffer.  The rate of thrombin generation was measured 
using a chromogenic substrate, Spectrozyme TH (0.4nM), which probes for thrombin 
generation.  The initial rate of thrombin generation was analyzed with Prizm 
(GraphPad) software. 
2.3.12 Calculation of Factor Xa Saturation by Recombinant Factor Va Molecules 
     To order to compare prothrombinase function assembled in the presence of the 
various mutant recombinant molecules we have first calculated the kd of each species 
for factor Va as described above by titrating a fixed amount of factor Xa with 
increased concentrations of factor Va as described above.  Once the value of the kd of 
the interaction of each species of factor Va with factor Xa was determined, the 
amount of recombinant factor Va required to completely saturate factor Xa and 
provide similar amount of enzyme (prothrombinase) when using various factor Va 
recombinant molecules (between 95% - >99% saturation) can be calculate as 
abundantly described in the literature (22).  Briefly, the kd for the factor Va-factor Xa 
interaction is given by the equation: 
[ ] [ ]
[ ]XaVa
XaVaK FFd •
⋅=  (1) 
The maximum amount of factor Xa saturated with factor Va formed under the 
conditions used can be verified by replacing in equation (1) [Va]F and [Xa]F by: 
[ ]Va F = [ ]Va T - [ ]XaVa •  (2) 
[ ]Xa F = [ ]Xa T - [ ]XaVa •  (3) 
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where, [Va]F and [Xa]F are the concentrations of free factor Va and factor Xa, while 
[Va]T and [Xa]T are the total concentrations of factor Va and factor Xa respectively.  
The final concentration of factor Xa within the mixture was 1nM and the maximum 
amount of factor Xa saturated with factor Va formed under the above conditions was 
extrapolated from the following equation directly.   
[ ] [ ][ ] [ ][ ] [ ][ ] [ ] [ ][ ]
2
42 TTdTTdTT
bound
XaVanKXaVanKXaVan
Xa
⋅⋅⋅−++⋅−++⋅=
 (4) 
with the Kd for the bimolecular interaction between factor Va and factor Va on a 
phospholipid surface calculated from the functional titration described above and the 
concentration of [Va]T modified as appropriate (53).  Throughout all experiments the 
assumption was n  = moles of factor Xa bound/mole of factor Va at saturation; 
throughout this study n  = 1; the stoichiometry of the factor Va-factor Xa interaction 
was fixed at 1. 
2.3.13 Calculation of Additive Effect of the Mutations on Prothrombinase 
Function 
     The change in transition-state stabilization free energy, which measures the effect 
of the mutations in the cofactor of the prothrombinase complex have on the catalytic 
site of the enzyme, was calculated for the double mutants as extensively described 
previously (22).  In brief, the perturbation to the function of prothrombinase 
assembled with wild type factor Va (state A) caused by a mutation in factor Va (state 
B) affecting the transition state can be defined in general as follows: 
ABB GGG ∆−∆=∆∆   (Eq. 1) 
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and since prothrombinase activity (assembled with each of the recombinant factor Va 
proteins) is being measured against the same substrate (prothrombin), the transition-
state stabilization free energy (∆∆G‡A→B) during catalysis induced by a mutation in 
factor Va can be determined from the following equation: 
∆∆G‡A→B = - RT ln [(kcat/Km)B/(kcat/Km)A] (Eq. 2) 
where R is the universal gas constant (2 cal•K-1•mol-1), T is the absolute temperature 
(298 K in the experiments presented here), kcat is the turnover number, and Km is the 
Michaelis Menten constant of the reaction.  Once calculated, these values can be used 
to determine ∆∆Gint, which reflects the exchange in free energy between the amino 
acids side chains manipulated in this study (E323F, Y324F, E330M, V331I, D334K, 
and Y335F) by the following equation: 
∆∆Gint = ∆∆G‡A→B/C – (∆∆G‡A→B + ∆∆G‡A→C)   (Eq. 3) 
A positive value of ∆∆Gint indicates that the interaction of these amino acid side 
chains reduce the catalytic efficiency of prothrombinase, negative value demonstrates 
that the mutations are better for prothrombinase, resulting in an increase in the 
catalytic efficiency of the enzyme.  A value of zero would indicate no effect. 
2.3.13 Prothrombin Activation Measured by Gel Electrophoresis  
     Prothrombin was incubated in a reaction mixture containing the following: 20µM 
PCPS, 50µM DAPA, and 10nM of factor VaWT, factor VaKF, and factor VaAA and 
30nM of factor VaFF/KF, factor VaMI/KF, factor VaFF/AA, and factor VaMI/AA (activated 
with thrombin) in TBS, Ca2+.  A zero point was taken and the addition of 1 nM factor 
Xa marked the start of the reaction.  Aliquots of the reaction mixture will be removed 
at selected time points  (0:20, 0:40, 1:00, 1:20, 1:40, 2:00, 2:20, 2:40, 3:00, 3:20, 
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3:40, 4:00, 5:00, 6:00, 10:00, 20:00, 30:00 and 60:00 minutes) and added to two 
volumes 0.2M glacial acetic acid.  The samples will be dried in a centrivap and 
reconstituted in 0.1M Tris base, pH 6.8, 1% SDS, 1% β-mercaptoethanol and heated 
for exactly 75 seconds at 950C.  A total of 5µg of total protein will be loaded per lane 
and analyzed on 9.5% SDS-PAGE followed by staining with Coomassie Blue. 
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2.4 Results 
2.4.1 Inhibition of Prothrombinase Function by Synthetic Peptides from the 
Central Portion of Factor Va Heavy Chain.   
     Our laboratory has previously shown that a peptide representing amino acid 
residues 323-331 inhibits factor Va cofactor activity (13).  We have extensively 
characterized the important amino acids from this region by site directed mutagenesis 
(21).  Our research group has also shown that under the experimental conditions 
employed, while peptides encompassing region 327-336 (AP5) and 332-341 (AP6) of 
factor Va heavy chain also inhibit factor Va cofactor activity, the pentadecapeptide 
P15H (representing amino acids 337-351 of factor V) did not have any effect on 
factor Va activity and was a good negative control (13).  Our laboratory have thus 
hypothesized that the overlapping sequence between AP5 and AP6 (amino acid motif 
332IWDYA336) may contain amino acids responsible for the inhibition of 
prothrombinase.   
     To investigate if the peptides from the heavy chain of factor Va, N42R, AP3, AP5, 
and AP6 were able to directly interact with factor Xa, chemical cross-linking with 
EDC was used.  Active site blocked, factor Xa (factor Xa-EGR) was incubated with a 
25 molar excess of the peptides in the presence of lipids and the cross-linker EDC.  
The results show in Figure 2.3, that the peptide N42R was able to bind to both the 
heavy chain (Mr = 42,000) and the light chain (Mr = 16,5000) of factor Xa in a spot 
outside of the active site of the enzyme (lane one depicts factor Xa-EGR alone, and 
lane two shows factor Xa-EGR plus N42R).  Under the same experimental 
conditions, the peptides AP4, AP5, and AP6 did not display the chemical cross-
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linking with EDC due to the low molecular weight of the peptides there was not 
enough of a difference in the molecular weight between factor Xa-EGR and factor 
Xa-EGR-cross-linked (data not shown).  These results demonstrates that peptides 
from the heavy chain of factor Va are able to directly bind to factor Xa in a spot 
distant from the active site of the enzyme.   
     To investigate the role of these amino acids as it pertains to prothrombinase 
assembly and function, we have initiated a series of experiments using peptides from 
this region.  The peptides were assayed for their ability to inhibit prothrombinase 
activity in assay that uses purified reagents and a fluorescent thrombin inhibitor 
(Figure 2.4).  The data demonstrate that AP5 inhibits prothrombinase with an IC50 of 
15 µM (Figure 2.4, filled diamonds) while the control peptide (P15H) had no effect 
on prothrombinase activity under the conditions employed even at concentrations as 
high as 500 µM (Figure 2.4, closed circles).  Complete inhibition of prothrombinase 
by AP5 occurred at 200 µM peptide.  The Ki of inhibition calculated from the IC50 
was 8 µM. 
     In view of these results we have synthesized an additional peptide (IWDYA, I5A) 
and assayed its capability to inhibit prothrombinase activity.  I5A inhibited cofactor 
activity, although not completely.  Even at 500 µM peptide there was still 
approximately 25% cofactor activity remaining (Figure 2.4, closed squares).  The data 
demonstrated that AP6 and IWDYA have similar Ki values of 64 µM and 69 µM 
respectively.  The similar Ki values between AP6 and IWDYA suggest that the 
inhibitory effect of the peptides is caused by the shared amino acid 
sequence332IWDYA336.  To understand the effect of the amino acid sequence of this 
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pentapeptide on cofactor activity we have synthesized another peptide with the 
sequence DY replaced by KF (AP5DY→KF, AP5m) and assayed the peptide for 
prothrombinase inhibition.  AP5m had only a weak effect on prothrombinase function 
with ~60% cofactor activity remaining at concentrations of peptide as high as 500 µM 
(Figure 2.4, closed triangles), with a Ki value of ~530 µM.  These data indicate that 
residues 334-335 are important for the expression of the inhibitory potential of AP5.  
Taken together, the results indicate that 1) peptide AP5 from the central portion of the 
factor Va heavy chain is a potent inhibitor of factor Va cofactor activity; and 2) 
residues 334-335 from factor Va heavy chain have a crucial role for optimum 
expression of prothrombinase activity. 
     Next, the ability of the peptides to accelerate the activation of prothrombin by 
factor Xa was investigated.  The peptides were pre-incubated with prothrombin, 
DAPA, and lipids in TBS, Ca2+, pH 7.40.  Factor Xa was used to start the reaction 
and the peptides were analyzed over a three-hour time course as described in 
Experimental Procedures.  Control experiments with plasma factor Va and factor Xa 
alone show the expected results.  Factor Xa alone cleaves first at Arg271 showing the 
intermediates Fragment 1.2 and Prethrombin-2 followed by cleavage at Arg320 
producing thrombin (Figure 2.5) and the addition of factor Va reverses the order of 
these cleavages, cleaving first at Arg320 to produce the intermediate meizothrombin 
followed by cleavage at Arg271 to produce thrombin (Figure 2.5).  The addition of the 
control peptide, P15H, does not have an effect on prothrombin activation as compared 
to factor Xa alone (Figure 2.5).  Addition of the heavy chain peptides, N42R and AP3 
show an increase in prothrombin disappearance and thrombin generation as compared 
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Figure 2.3 EDC Cross-Linking.  To investigate if a peptide from factor Va heavy 
chain, N42R, interacts with factor Xa, chemical cross-linking with EDC was used.  
Factor Xa with the active site blocked, FXa-EGR, was incubated by itself (Lane 1) or 
with a 25 molar excess of N42R (Lane 2), in the presence of lipids.  Reducing SDS-
PAGE, followed by staining with Coomassie Blue, then separated the protein.  The 
results show that N42R was cross-linked to FXa-EGR on both the heavy (Mr = 
42,000) and light chains (Mr = 16,500).  
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Figure 2.4 Peptide Inhibition. Increasing concentrations of AP5, P15H, I5A, and 
AP5DY→KF were preincubated with factor Xa and assayed for prothrombinase activity 
as described in the “Experimental Procedures” section.  The final concentration of 
factor Xa in the mixture was 10 nM.  P15H (filled circles) represents the control 
peptide, amino acids 337-351 of human factor Va heavy chain.  AP5 (filled 
diamonds) represents amino acid region 327-336.  AP5DY→KF (filled triangles) 
represents amino acid residues 327-336 with residues 334-335 mutated from DY to 
KF.  IWDYA (filled squares) is amino acid residues 332-336 of human factor Va 
heavy chain.  The concentration of peptide given on the x axis represents its final 
concentration in the prothrombinase mixture.  The data represent the average of the 
results found in three independent experiments.  The apparent inhibition constant (Ki) 
reported in the text is the value calculated from the formula: IC50=Ki(1+S0/Km), 
where Km is the Michaelis-Menten constant of the reaction in the absence of inhibitor, 
S0 is the concentration of prothrombin used, and IC50 is the half maximal inhibition of 
prothrombinase by a given peptide.  
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Peptide IC50 (µM) Ki (µM) 
AP5 15 8 
AP5  DY→ KF 1000 530 
AP6 120 64 
IWDYA 130 69 
 
 
 
 
 
 
Table 2.1 Peptide Inhibition Constants.  The IC50 values for AP5, AP5DY→KF, AP6, 
and IWDYA were calculated from inhibition experiments (Figure 2.3).  The IC50 
value is the concentration of the peptide at 50% inhibition.   
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to factor Xa alone.  In addition, the peptides AP5 and AP6 also show an increase in 
prothrombin activation, but not to the extent of N42R and AP3 (Figure 2.5).  On the 
other hand, AP5m, which as the DY→KF substitution, does not show any increase in 
prothrombin activation as compared to factor Xa alone; indicating that residues 
334DY335 are important to factor Va cofactor activity (Figure 2.5).  In order to 
compare the prothrombin activation scheme by the different heavy chain peptides, 
one time point was chosen for each peptide and control and the results were run on 
the same gel (Figure 2.6).  The results clearly show that peptides from the factor Va 
heavy chain, N42R and AP3, accelerate Pathway I of prothrombin cleavage compared 
to factor Xa alone; demonstrated by increased Prethrombin-2 accumulation indicative 
of first cleavage at Arg271.  The factor Va reaction displays the expected fragments of 
prothrombin activation following Pathway II, accumulation of Fragment 1.2A 
(meizothrombin under reducing conditions) followed by thrombin generation.  This 
result suggests that small portion of factor Va represented by the peptides analyzed 
here increases the activity of the enzyme, factor Xa, alone and that it must be another 
portion of the cofactor that accelerates the factor Va directed prothrombin activation 
pathway. 
2.3.3 Confirmation Amino Acid Residues 334-335 are the Important Residues 
From Region 332-336 From Factor Va Heavy Chain. 
    To ascertain that amino acid residues 334-335 from the IWDYA peptide are 
responsible for the effect observed, recombinant molecules were made at residues 332 
(factor VI332A) and 333 (factor VW333A).  These recombinant molecules were assessed 
for their ability to assemble in the prothrombinase complex and bind the enzyme, 
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Figure 2.5 Prothrombin Activation by Factor Va Heavy Chain Peptides. The 
peptides (50µM N42R, 100µM P15H, 100µM AP3, 100µM AP5, 100µM AP6, and 
100µM AP5m) and plasma factor Va (10nM) were allowed to pre-incubate with 
factor Xa (1nM) in the presence of PCPS (20µM) and DAPA (3µM) and the reaction 
was started by the addition of prothrombin (1.4µM) as described in “Experimental 
Procedures”.  Each experiment was done in triplicate with different dilutions of 
peptides and one representative gel is shown. 
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Figure 2.6 Comparing Prothrombin Activation Between Factor Va Heavy Chain 
Peptides.  Plasma factor Va and the peptides, 50µM N42R, 100µM P15H, 100µM 
AP3, and factor Xa alone were pre-incubated with 1nM factor Xa, 20µM PCPS, and 
3µM DAPA in TBS, Ca2+, pH 7.40 for 5 minutes at room temperature.  Aliquots 
were removed at the following time points, 3min and 30min for plasma factor Va, and 
one hour for the peptides and factor Xa alone as described in “Experimental 
Procedures”. 
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factor Xa, in a discontinuous assay.  The results show similar kd values for factor 
VI332A and factor VW333A, indicating these residues are not involved in the binding of 
the cofactor to the enzyme in the prothrombinase complex (Figure 2.7, Table 2.2).  
Next, the capability of factor VI332A and factor VW333A to assemble in the 
prothrombinase complex and bind the substrate, prothrombin, and the catalytic 
efficiency was measured in a discontinuous assay.  Similarly, these results show that 
these residues are not involved in substrate binding as indicated by similar Km values 
and catalytic efficiencies (Figure 2.8, Table 2.2).  Taken together, these results 
indicate that amino acid residues 332-333 from the central portion of factor Va heavy 
chain, specifically within the peptide IWDYA, are not involved in cofactor function.  
Thus, it can be deduced that it is definitely amino acid residues 334-335 that are 
important for the expression of inhibitory potential of amino acid region IWDYA. 
2.4.3 Transient Expression and activation of recombinant human factor V 
molecules.   
     We next employed a recombinant protein scheme to further evaluate the 
importance of amino acid residues 334-335 of factor Va heavy chain to cofactor 
activity.  We used one charge reversal mutation (D334K) and one conservative 
mutation (Y335F) to obtain recombinant factor VKF.  In addition, we also mutated 
residues 334-335 to alanines.  We have also combined these resulting recombinant 
mutant molecules with previously characterized recombinant proteins, factor VMI and 
factor VFF that are deficient in factor Xa binding.  We have thus obtained the 
quadruple mutants, factor VMI/KF,  factor VFF/KF, factor VMI/AA, and factor VFF/AA (21).  
We first analyzed the recombinant proteins for clotting activity and the results are 
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shown in Table2.3.  In a two-stage clotting assay, recombinant wild type factor Va 
displayed normal clotting times, compared to plasma derived factor Va at a 
concentration of 2.5nM (580-700 U/mg).  Conversely, while factor VaKF and factor 
VaAA had a reduced clotting activity under similar experimental conditions (57-100 
U/mg), the quadruple mutants, factor VaMI/KF, factor VaFF/KF, factor VaMI/AA, and 
factor VaFF/AA were severely impaired in their clotting activities (≤8 U/mg).  These 
results demonstrate that while mutation of amino acids residues 334-335 severely 
impairs clotting activity, these mutations alone are not enough to completely abolish 
factor Va clotting activity.  However, combining these mutations with mutations at 
the extremities of the previously described factor Xa binding site (22), results in 
cofactor molecules that are deficient in their clotting activity.   
2.4.4 The Effect of Recombinant Factor Va molecules on Prothrombin 
Activation by prothrombinase.   
     The capability of the recombinant factor Va molecules to incorporate into 
prothrombinase and activate prothrombin was investigated by gel electrophoresis.   
Prothrombinase assembled with purified recombinant wild type factor Va displayed 
the normal activation pattern of prothrombin by the prothrombinase complex as 
compared to plasma derived factor Va (Figure 2.9, top panel) with initial cleavage at 
Arg320 producing fragment 1•2-A.  This fragment is rapidly consumed following 
cleavage at Arg271 to produce fragment 1•2 and the active product, thrombin.  
Activation of prothrombin by prothrombinase assembled with purified factor VaKF 
and factor VaAA showed delayed thrombin formation as evidenced by delayed 
formation fragment 1•2-A and B chain of thrombin.  Even after the one-hour time 
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Figure 2.7 : Factor Va Titrations to determine the affinity of the recombinant 
factor Va molecules for factor Xa.  Thrombin generation experiments were carried 
out as described under “Experimental Procedures”.  Prothrombinase complex 
assembled with varying concentrations (30 pM to 5 nM) of recombinant purified wild 
type factor Va is depicted by filled squares, purified recombinant factor VaI332A by 
filled inverted triangles, and  purified factor VaW333A by filled circles.   The solid lines 
represent a nonlinear regression fit of the data using Prizm GraphPad software for a 
one binding site model.  Titrations were performed in triplicate with at least four 
different preparations of purified and partially purified protein. 
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Figure 2.8 Prothrombin Titrations to determine the kinetic parameters of 
prothrombinase assembled with the various recombinant factor Va species.  
Thrombin generation experiments were carried out as described under “Experimental 
Procedures” by varying the substrate concentration (25 nM to 4 µM) with 5 pM of 
factor Xa saturated with the factor Va species.  Prothrombinase complex assembled 
with recombinant purified wild type factor Va (filled squares), purified recombinant 
factor VaI332A (filled inverted triangles), and  purified factor VaW333A (filled circles).  
The data shown are the average of five different titrations performed in triplicate with 
at least four different preparations of purified and partially purified proteins.   
 
 
 
II Titrations
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
0
1
2
3
4
5
6
7
8
9
10
11
12
13
10nM WT
10nM I332A
10nM W333A
[Prothrombin] mM
nM
 II
a 
/ m
in
 65
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2 Kinetic Constants.  The dissociation constants of recombinant factor Va 
species for plasma derived factor Xa were calculated at limiting concentrations of the 
enzyme as described in “Experimental Procedures”.  The Km constants were 
determined at described in “Experimental Procedures” using limiting amounts of the 
enzyme and varying concentrations of substrate. 
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point the fragment 1•2-A still persist (Figure 2.9, middle and bottom panel, 
respectively).  Under similar experimental conditions factor VaMI/KF, factor VaFF/KF, 
factor VaMI/AA, and factor VaFF/AA were unable to activate prothrombin, even 
following a 3-hour incubation period (Figure 2.10).  These results indicate that 
substitution of amino acid residues 334-335 of the factor Va heavy chain has a 
damaging consequence on factor Va cofactor activity, resulting in delayed 
prothrombin activation by factor Xa within prothrombinase.  Overall these results 
indicate that amino acid residues 334-335 are essential for optimal conditions of 
prothrombin activation by prothrombinase. 
2.4.5 Kinetic Analyses of Prothrombinase assembled with Recombinant Factor 
Va.   
     The capability of the recombinant factor Va molecules to be incorporated in 
prothrombinase was investigated using an assay employing purified reagents.  We 
have purified the recombinant wild type cofactor and mutants factor VKF and factor 
VaAA and compared the kinetic data obtained with these molecules to the data 
obtained with prothrombinase assembled with the partially purified factor Va 
molecules following activation by thrombin.  No significant differences were 
observed when comparing the numbers obtained with the two different recombinant 
factor Va molecules (Figure 2.11, Table 2.4).  These data demonstrate that the 
partially purified cofactor displays similar kinetic behavior as the purified cofactor 
molecule.  Under similar experimental conditions, purified factor VaKF and factor 
VaAA displayed a comparable KD value to the wild type molecule (Table 2.3).   
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Plasma Factor Va 
Species 
Two-Stage 
Clotting Time 
Activity (U/mg) 
Factor Vaplasma 15.5±1.10 698 
Factor VaWT 18.6±0.81 597 
Factor VaKF 34.5±1.23 68 
Factor VaAA 32.1±1.36 79 
Factor VaFF/KF 59.6±2.36 ≤8 
Factor VaFF/AA 56.3±1.78 ≤8 
Factor VaMI/KF 62.1±3.12 ≤8 
Factor VaMI/AA 60.4±2.65 ≤8 
 
 
Table 2.3 Clotting Times and Activities of Recombinant Factor Va Molecules.  
The clotting times and activity were determined as described in ‘Experimental 
Procedures’.  Factor V-deficient plasma was used and the recombinant proteins were 
analyzed at a final concentration of 2.5nM. 
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Figure 2.9 Prothrombin Activation Analysis by Gel Electrophoresis. 
Recombinant factor Va molecules, factor VaWT,   factor VaKF, and factor VaAA were 
incubated with prothrombin, PCPS vesicles, and DAPA as detailed in the 
“Experimental Procedures” section at a final concentration of 10 nM.  Factor Xa was 
added to start the reaction to a final concentration of 1nM.  Aliquots were withdrawn 
at given time intervals and treated as described in the “Experimental Procedures”.  
The legends to the right of the gels indicate the prothrombin activation fragments: II 
(prothrombin), F1•2A (Fragment 1•2-A chain), F1•2 (fragment 1•2), and B (B chain 
of thrombin), Experiments were performed with least three preparations of purified 
proteins and one representative gel is shown. 
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Figure 2.10 Prothrombin Activation Analysis by Gel Electrophoresis With The 
Quadruple Mutants.  Recombinant factor Va molecules, factor VaWT, factor VaFF/KF, 
factor VaFF/AA, factor VaFF/AA, and factor VaMI/AA were incubated with prothrombin, 
PCPS vesicles, and DAPA as detailed in the “Experimental Procedures” section at a 
final concentration of 30 nM.  Factor Xa was added to start the reaction to a final 
concentration of 1nM.  Aliquots were withdrawn at given time intervals and treated as 
described in the “Experimental Procedures”.  The legends to the right of the gels 
indicate the prothrombin activation fragments: II (prothrombin), F1•2A (Fragment 
1•2-A chain), F1•2 (fragment 1•2), and B (B chain of thrombin), Experiments were 
performed with least three preparations of purified proteins and one representative gel 
is shown. 
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     Conversely, the quadruple mutant recombinant factor Va molecules showed 
significant decreases in the kd values. The affinities of factor VaMI/KF, factor VaFF/KF, 
factor VaMI/AA, and factor VaFF/AA were approximately 6-fold, 14-fold, 19-fold, and 
10-fold respectively lower than the affinity of the wild type cofactor molecule for 
factor Xa.  These latter data are in good agreement with our recent results, and 
demonstrate that amino acids 334-335 do not participate in the interaction of the 
cofactor with factor Xa (21).   
     Figure 2.12 shows the initial steady-state rate of prothrombin activation as a 
function of substrate concentration.  The average kinetic constants obtained in several 
experiments using at least four different preparations of each recombinant cofactor 
molecule, are provided in Table 2.3.  The data show that all mutant recombinant 
factor Va species have a small but significant effect on the Km of the reaction as 
compared to the wild type cofactor (Figure 2.12 and Table 2.4).  While our recent 
data using prothrombinase assembled with factor VaFF, factor VaMI, and factor 
VaFF/MI demonstrated similar Km values to the data obtained with prothrombinase 
assembled with the plasma and the wild type recombinant factor Va molecules (~0.15 
µM, ref), all the data obtained using the mutant factor Va molecules containing the 
334DY335→ KF substitution, have a 4-fold higher Km value than prothrombinase 
assembled with the wild type cofactor (Table 2.4).  The data suggest that 
prothrombinase assembled with these mutant molecules is impaired in its interaction 
with the substrate.  Furthermore, prothrombinase assembled with purified factor VaKF 
and factor VaAA was characterized by a ~1.6-fold and 2-fold decrease, respectively in 
the kcat of the reaction (Figure 2.13).  Furthermore, prothrombinase assembled with 
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Figure 2.11 Factor Va Titrations to determine the affinity of the recombinant 
factor Va molecules for factor Xa.  Thrombin generation experiments were carried 
out as described under “Experimental Procedures”.  Prothrombinase complex 
assembled with varying concentrations (30 pM to 5 nM) of recombinant partially 
purified wild type factor Va (filled squares), purified recombinant factor VaWT (open 
squares), partially purified factor VaKF (filled triangles), purified factor VaKF (open 
triangles), purified factor VaAA (open circle), partially purified factor VaFF/KF (open 
inverted triangle), partially purified VaMI/KF (filled diamonds), partially purified factor 
VaMI/AA (filled circles), and partially purified factor VaFF/AA (open diamonds).   The 
solid lines represent a nonlinear regression fit of the data using Prizm GraphPad 
software for a one binding site model.  Titrations were performed in triplicate with at 
least four different preparations of purified and partially purified protein. 
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Figure 2.12 Prothrombin Titrations to determine the kinetic parameters of 
prothrombinase assembled with the various recombinant factor Va species.  
Thrombin generation experiments were carried out as described under “Experimental 
Procedures” by varying the substrate concentration (25 nM to 4 µM) with 5 pM of 
factor Xa saturated with the factor Va species.  Prothrombinase complex assembled 
with recombinant partially purified wild type factor Va (filled squares), purified 
recombinant factor VaWT (open squares), partially purified factor VaKF (filled 
triangles), purified factor VaKF (open triangles), purified factor VaAA (open circle), 
partially purified factor VaFF/KF (open inverted triangle), partially purified VaMI/KF 
(filled diamonds), partially purified factor VaMI/AA (filled circles), and partially 
purified factor VaFF/AA (open diamonds).  The data shown are the average of five 
different titrations performed in triplicate with at least four different preparations of 
purified and partially purified proteins.   
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Table 2.4 Kinetic Constants of Recombinant Factor Va Molecules.  The 
dissociation constants of recombinant factor Va species for plasma derived factor Xa 
were calculated at limiting concentrations of the enzyme as described in 
“Experimental Procedures”.  The Km constants were determined at described in 
“Experimental Procedures” using limiting amounts of the enzyme and varying 
concentrations of substrate. 
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the quadruple mutant molecules, factor VaMI/KF and factor VaFF/KF, demonstrated a 
significant decrease in the kcat of the enzyme with prothrombinase assembled with 
factor VaMI/KF always being the most impaired in its catalytic efficiency (Table 2.4).  
Overall the data demonstrate that substitution of amino acids 334-335 in factor Va 
has a profound effect on the catalytic efficiency of prothrombinase, decreasing the 
second order rate constant of the reaction by ~6-fold.  The inability of prothrombinase 
assembled with factor VaKF to function optimally can be explained by both the 
inability of factor Xa to efficiently convert prothrombin to thrombin because of 
diminished productive collisions (difference in kcat) and because of impaired 
prothrombinase-substrate interaction (increase in the Km). 
2.4.6 Additive Effect of the mutations on prothrombin catalysis.   
     Prothrombinase is composed of factor Va and factor Xa assembled on a membrane 
surface in the presence of divalent metal ions.  We can thus assume that 
prothrombinase is an enzyme composed of two subunits: a catalytic subunit (factor 
Xa) and a regulatory subunit (factor Va).  Any perturbation in the interaction between 
the two subunits or any perturbations in the interaction of prothrombinase with the 
substrate caused by a mutation may influence (modify) the stability of the catalytic 
site of the enzyme.  The kinetic data showed that combining the DY→KF mutations 
in the regulatory subunit of prothrombinase with the mutations in either of the other 
two factor Xa-binding sites previously described result in a dramatic decrease of the 
catalytic efficiency of prothrombinase.  Thus, the consequences of mutations in factor 
Va affecting factor Xa catalytic efficiency and their additivity can be measured 
relative to the change in transition-state stabilization free energy (∆∆G‡) of the  
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Figure 2.13 Graphical Representation of Catalytic Efficiencies of the 
Recombinant Factor Va Molecules.  The values of kcat were determined using the 
kd’s and the quadratic equation to determine the saturation concentration of the 
various recombinant factor Va species. 
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Figure 2.14 Graphical Representation of Second Order Rate Constants of 
Recombinant Factor Va Molecules.  The second order rate constants were 
determined by dividing the kcat by the Km. 
 
 
 
Comparison of Second Order Rate
Constants
WT FF MI KF AA FF-KF FF-AA MI-KF MI-AA
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50
2.75
3.00
Recombionant Factor Va Molecules
k c
at
/K
m
 x
 1
0-
7  
(s
-1
M
-1
)
 77
enzyme as previously established (22).  To quantify the interaction between the 
mutations and their synergistic effects on prothrombinase function, we have 
calculated the difference in free energy of the transition state analog (∆∆Gint) for each 
of the double mutant according to Equations 2 and 3 (described in the experimental 
procedures section and we have also constructed a thermodynamic cycle for cleavage 
of prothrombin by prothrombinase (Figure 2.14).  The positive value of ∆∆Gint for the 
combination of mutations indicates that mutation of amino acids in the heavy chain of 
factor Va are disruptive and detrimental to the catalytic activity of prothrombinase.  
Moreover, the nearly 2-fold increase in the ∆∆Gint for prothrombinase assembled with 
factor VaMI/KF compared with the ∆∆Gint obtained for prothrombinase assembled with 
factor VaFF/KF is in agreement with the kinetic data, and our recent results denoting 
the critical contribution of amino acids 330-331 to prothrombinase assembly and 
function (21). 
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Figure 2.15 Additive Effect of Recombinant Proteins on Prothrombin Catalysis.  
∆∆Gint  is the enery of interaction between the side chains of 323EY324 and 334DY335 
and 330EV331 and 334DY335 of factor Va heavy chain and was calculated as described 
under “Experimental Procedures”. 
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2.5 Discussion 
     Collectively, through a systematic approach using both kinetic studies with 
synthetic peptides and recombinant proteins, our data demonstrate that amino acid 
residues D334 and Y335 are crucial for optimum re-arrangement of enzyme and 
substrate required for efficient catalysis of prothrombin by prothrombinase.  These 
residues are conserved throughout evolution, being identical in human, bovine and 
porcine species, indicating their importance to factor Va cofactor function.   
The mechanism of inhibition of prothrombinase function by AP5, AP5DY→KF, 
IWDYA, and P15H was investigated by assessing factor Va cofactor activity in the 
presence of increasing concentrations of synthetic peptide.  Our previous data 
suggested that amino acid region 332IWDYA336 may contribute to the activity of 
prothrombinase (22).  The present data show that the IWDYA motif shared by AP5 
and AP6 contains the amino acids accountable for the inhibitory effect of the 
peptides.  This is indicative by the similar Ki values of peptides AP6 and IWDYA.  
AP5 has an 8-fold lower Ki value than AP6 and I5A, because it also contains amino 
acids Glu330 and Val331, which have been previously shown to be involved in factor 
Xa binding (21).  Analysis of the mode of inhibition of prothrombinase by AP5 
suggests that the peptide is a mixed type inhibitor and interacts with both 
prothrombinase and prothrombinase bound to the substrate (prothrombin).  Thus, 
while it is possible that AP5 interacts with prothrombinase in the presence and 
absence of prothrombin, the possibility that AP5 also binds prothrombin when the 
enzyme is in complex with the substrate must be kept in mind.  Finally, within the 
peptide sequence IWDYA, amino acids DY are crucial for its function, since 
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substitution of these two amino acids by KF results in the almost complete loss of the 
inhibitory potential of AP5 (AP5DY→KF). 
     Site directed mutagenesis was next used to assess the importance of amino acids 
334-335 from factor Va heavy chain during prothrombin catalysis.  The data show that 
mutating these amino acids results in a factor Va molecule that when incorporated into 
a prothrombinase produces a prothrombinase with altered Km and kcat.  In addition, the 
study of prothrombin cleavage by prothrombinase by gel electrophoresis assembled 
with factor VaKF and factor VaAA demonstrated approximately an 8-fold lower rate of 
prothrombin cleavage than prothrombinase assembled with the wild type cofactor 
molecule.  Since the KD of factor VaKF and factor VaAA is similar to the KD of the wild 
type molecule, these data like the kinetic data strongly suggest that amino acids 334 
and 335 from factor Va heavy chain are involved in the interaction of the enzyme 
(prothrombinase) with the substrate (prothrombin).  It has been further confirmed that 
it is indeed amino acid residues, 334-335, by recombinant protein data with factor 
VaI332A and factor VaW333A.  These recombinant proteins displayed similar kinetic 
activity when compared to the wild type molecule.  
     Our data reveal that, although amino acid substitution at amino acid residues 334-
335, is enough to produce an effect on cofactor function, it takes substitution at four 
amino acids (323-324 and 334-335 or 330-331 and 334-335) in order to completely 
abolish factor Va cofactor activity.  The kinetic data show that the quadruple factor Va 
mutants, factor VaMI/KF, factor VaFF/KF, factor VaMI/AA, and factor VaFF/AA, have a 
reduced affinity for the enzyme factor Xa, having 5- to 20-fold increased kd values.  In 
addition, these recombinant proteins have a 10-fold or greater decrease in their 
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catalytic efficiencies.  On the other hand the quadruple mutants do no have any 
impairment in their ability to bind the substrate, prothrombin’ the Km of all the 
reactions is the same.  Since factor VaMI/KF, factor VaFF/KF, factor VaMI/AA, and factor 
VaFF/AA are only damaged in their interaction with factor Xa, it can be concluded that 
the cofactor, factor Va, plays a role in prothrombinase assembly and function by 
rearranging the enzyme into the most favorable position to cleave two distant sites 
(36Ǻ) on the substrate (22, 23). 
     The thermodynamic data presented herein imply that mutation at residues Glu323 
and Tyr324 or Glu330 and Val331 together with Asp334 and Tyr335 have a collective effect 
on prothrombin activation.  The data also suggest that the side chains of these amino 
acids act synergistically to stabilize the transition state complex of the reaction.  
However, it cannot be ruled out that the change in free energy following mutation at 
the specified amino acids is not due to a conformation change of the protein. 
     Collectively, the data demonstrate that amino acids 334-335 of factor Va play a 
crucial role for the expression of factor Va cofactor activity and demonstrated the 
cofactor requirement for the efficient rearrangement of enzyme (factor Xa) and 
substrate (prothrombin) within prothrombinase required for efficient catalysis.  Thus, 
one more time our data strongly suggest that factor Va directs (regulates) catalysis of 
prothrombin by factor Xa within prothrombinase. 
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CHAPTER III 
THE LONG-RANGE RELATIONSHIP BETWEEN IMPORTANT AMINO 
ACID REGIONS OF FACTOR VA HEAVY CHAIN 
 
 
3.1 Abstract 
     The prothrombinase complex catalyzes the activation of prothrombin to thrombin.  
The incorporation of the cofactor, factor Va, into the prothrombinase complex 
increases the catalytic efficiency of the enzyme by five orders of magnitude.  Thus, 
the proper interaction of factor Va with the members of the prothrombinase complex 
results in timely thrombin formation at the place of vascular injury.  We have 
previously shown that amino acid region 695DYDYQ699 of the COOH-terminus of 
the heavy chain of factor Va plays an important role during factor V activation and is 
required for optimal prothrombinase function.  We have also demonstrated that amino 
acid region 334DY335 are required for optimum activity of prothrombinase.  In 
 86
addition, we have structural data demonstrating that residues 334-335 and 695-699 of 
factor Va are in close proximity on the surface of the heavy chain of the cofactor.  In 
order to assess the effect of these residues we created recombinant factor Va 
molecules, combining mutations at amino acid residues 334-335 and 695-698 as 
follows: factor V
3K
 (334DY→KF335 and 695DYDY→KFKF698), factor V
K4
 
(334DY→KF335  and 695DYDY→AAAA698), and factor V
6A
 (334DY→AA335  
and 695DYDY→AAAA698).  These recombinant factor V molecules were 
transiently expressed into COS7 cells, purified to homogeneity by affinity 
chromatography, and assessed for cofactor activity in the presence of saturating 
concentrations of recombinant factor Va and limiting concentrations of factor Xa.  
SDS-PAGE and Western Blotting verified the integrity of the recombinant factor Va 
molecules with monoclonal antibodies specific to the heavy and light chains.  Kinetic 
analysis revealed that factor Va
3K
, factor Va
K4
, and factor Va
6A
 had a reduced affinity 
for the enzyme, factor Xa, when compared to the affinity of the wild type molecule 
for the enzyme.  In addition, prothrombinase assembled with a saturating 
concentration of factor Va
3K
 had a 10-fold reduced second order rate constant for 
prothrombin activation compared to the value obtained with prothrombinase 
assembled with the wild type molecule.  On the other hand, prothrombinase 
assembled with factor Va
KF/4A
 and factor Va
6A
 had approximately 1.5-fold reduced 
second order rate constant.  Overall, the data demonstrate that the inability of 
prothrombinase assembled with factor Va
3K
, factor Va
K4
, and factor Va
6A
 to function 
optimally can be explained by the inability of factor Xa to efficiently convert 
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prothrombin to thrombin because of diminished productive collisions due to defective 
interaction between factor Xa and prothrombin. 
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3.2 Introduction 
     Thrombin is necessary for continued existence and is formed following activation 
of its inactive precursor, prothrombin, by the prothrombinase complex.  The 
prothrombinase complex is composed if the enzyme, factor Xa and the protein 
cofactor, factor Va, assembled on a membrane surface in the presence of divalent 
metal ions.  Even though, factor Xa alone can activate prothrombin, the rate of this 
reaction is not compatible with survival.  On the other hand, incorporation of the 
cofactor into the prothrombinase complex increases the catalytic efficiency of 
prothrombin activation by 5 orders of magnitude, thus providing the physiological 
pathway for thrombin production.  This increase is believed to be the result of a 100-
fold decrease in the Km and a 3,000-fold increase in the kcat of the enzyme when 
compared to the enzyme, factor Xa, alone.  The decrease in the Km seems to be the 
outcome of a tighter interaction of the prothrombinase complex with the membrane 
surface, which results in higher local concentrations of the enzyme and the increase in 
the kcat of prothrombinase can be credited to the productive interaction between factor 
Va and factor Xa thus causing conformational changes in the enzyme complex (1-3). 
     It has long been established that factor Va is essential for suitable and specific 
activation of prothrombin, however the exact molecular mechanism by which factor 
Va exerts its cofactor function is still under investigation.  Many independent 
laboratories have established the beneficial interaction of factor Va within the 
prothrombinase complex.  In addition, the interaction of the heavy chain of factor Va 
with prothrombin involves anion binding exosite I of prothrombin has also been 
demonstrated (4-7).   
 89
     It has been previously demonstrated by our laboratory that the COOH terminus of 
the factor Va heavy chain is important for factor V activation and essential for 
optimal cofactor activity (8).  Specifically, it has been demonstrated that amino acid 
region 680-709 is important for these functions (9-11).  This was demonstrated by 
using a factor V molecule activated with the purified protease from the venom of the 
snake Naja nigricollis nigricollis (NN), which cleaves factor V at Asp697, Asp1509, and 
Asp1514 to produce factor VNN composed of a Mr 100,000 heavy chain (amino acid 
residues 1-696) and a Mr 80,000 light chain (amino acid residues 1509/1514-2196) 
(11).  It has been demonstrated by our research group that factor VNN has reduced 
clotting activity and an increased Kd value of 4 nM when compared to factor V 
activated with thrombin (fVaIIa) (Kd ∼0.5nM) (12).  Further experiments showed that 
when factor VIIa is additionally cleaved by NN, there is a 60-80% reduction in 
cofactor activity. This reduction in activity has been hypothesized to be a direct result 
from the loss of crucial amino acids of the heavy chain that are released when cleaved 
by NN.  This region of the cofactor is highly acidic in nature and contains several 
tyrosine residues that have been shown to have potential to be involved in factor V 
activation by thrombin and proper cofactor function (13).  Our laboratory has further 
characterized the importance of this region of factor Va by a series of experiments 
beginning with peptide studies.  Five overlapping peptides, designated HC1-HC5, 
were constructed and characterized; specifically, HC3 (consisting of amino acids 690-
699) and HC4 (containing residues 695-704), were found to inhibit prothrombinase 
activity with IC50 values of 12 and 10 µM, respectively (14).  Both peptides were 
found to competitively inhibit prothrombinase with Ki values of 6.3 µM for HC3 and 
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5.3 µM for HC4  It was found that the overlapping region between peptides HC3 and 
HC4, amino acid motif 695DYDYQ699, is a potent inhibitor of prothrombinase 
function with an IC50 of 1.6 µM (8).  This region was further assessed by making a 
recombinant factor V molecule with the mutations Asp695 → Lys, Tyr696 → Phe, 
Asp697 → Lys, and Tyr698 → Phe, designated factor VKFKF.  Data demonstrated that 
factor VKFKF could only be partially activated by thrombin and was deficient in its 
interaction with prothrombin.  However, activation by RVV-V and factor Xa 
proceeded at a normal rate despite the impaired cofactor activity(8).   
     As demonstrated in Chapter II, we have discovered residues from the central 
portion of the heavy chain of factor Va to contain a binding site for factor Xa.  
Specifically, we have shown that amino acid residues 334-335 are crucial for cofactor 
function.  Analysis of peptides encompassing this amino acid region shows inhibitory 
potential with respect to prothrombin activation; specifically the peptide AP5 with the 
amino acid substitution DY → KF is unable to inhibit prothrombin activation, 
indicating that it is residues 334-335 that are required for cofactor function.  In 
addition, recombinant protein analysis demonstrates that factor VaKF and factor VaAA 
have similar affinities for factor Xa as indicated by their similar kd values compared 
to factor VaWT.   However, these molecules are impaired in their ability to activate 
prothrombin compared to the wild type cofactor, gel electrophoresis analysis shows 
sustained prothrombin and delayed thrombin appearance.  We also demonstrated that 
combining mutations at residues 334-335 with mutations at residues 323-324 and 
330-331 result in cofactor molecules that are completely diminished in their ability to 
effectively assemble in the prothrombinase complex and activate prothrombin.  These 
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results suggest that mutation at more than two amino acid residues is required to have 
a profound effect on cofactor function.  The present study was undertaken to 
understand the importance of two distinct important regions of factor Va heavy chain 
when acting in concert on prothrombinase assembly and function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92
3.3 Experimental Procedures  
3.3.1 Materials and Reagents 
     Diisopropyl-fluorophosphate (DFP), O-phenylenediamine (OPD)-dihydrochloride, 
N- [2-Hydroxyethyl] piperazine-N’-2-ethanesufonic acid (Hepes), Trizma (Tris base), 
and Coomassie Blue R-250, were purchase from Sigma (St. Louis, MO).  Factor V-
deficient plasma is from Research Protein Inc. (Essex Junction, VT).  Secondary anti-
mouse and anti-sheep IgG coupled to peroxidase were purchased from Southern 
Biotechnology Associates Inc. (Birmingham, AL).  L-α-phosphatidylserine (PS) and 
L-α-phosphatidylcholine (PC) were from Avanti Polar Lipids (Alabaster, AL).  
Chemiluminescent reagent ECL+ and Heparin –Sepharose were from 
AmershamPharmacia Biotech Inc. (Piscataway, NJ).  Normal reference plasma and 
chromogenic substrate Spectrozyme-TH were from American Diagnostica Inc. 
(Greenwich, CT).  Thromboplastin reagent was purchased from Organon Teknika 
Corp.  (Durham, NC).  Dansylarginine-N- (3-ethyl-1, 5-pentanediyl) amide (DAPA), 
human factor Xa, human thrombin, and human prothrombin were purchased from 
Haematologic Technologies Inc. (Essex Junction, VT).  Factor V cDNA was from 
American Type Tissue Collection (ATCC# 40515 pMT2-V, Manassas, VA).  All 
restriction enzymes were from New England Biolabs (Beverly, MA).  All molecular 
biology and tissue culture reagents, specific primers, and medium were from Gibco, 
Invitrogen Corp. (Grand Island, NY) or as indicated.  Human factor V monoclonal 
antibodies (αHFVHC#17 and αHFVLC#9) and monoclonal antibody αHFV#1 coupled 
to Sepharose were provided by Dr. Kenneth G. Mann (Department of Biochemistry, 
University of Vermont, Burlington, VT). 
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Figure 3.1 Schematic of Recombinant Factor Va Molecules.  This scheme displays 
the mutant recombinant factor V molecule constructed. 
 
 
 
 
 
 
 
     
 
A3 C1 C2 COOH A1 A2 
Arg709 Arg1545Arg1018
B 
Recombinant Factor V Molecules 
NH2 
Factor VWT  No Mutation 
Factor V3K  D334 → K, Y335 → F, D695 → K, Y696 → F, D697 → K, Y698 → F 
Factor VKF/4A   D334 → K, Y335 → F, D695 → A, Y696 → A, D697 → A, Y698 → A 
Factor V6A   D334 → A, Y335 → A, D695 → A, Y696 → A, D697 → A, Y698 → A 
    
680KMHDRLEPEDEESDADYDYQNRLAAALGIR709
KFKF or AAAA 
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3.3.2 Construction of Recombinant Factor V Molecules 
     Factor VKFKF and factor VAAAA were constructed previously by our laboratory (8).   
Recombinant factor V molecules, Factor V3K, factor VKF/4A, and factor V6A were   
constructed using Stratagene’s QuikChange® XL Site-Directed Mutagenesis Kit.  
Factor V3K was constructed using the mutagenic primers, 5’-C ATT TGG AAG TTT 
GCA CCT G-3’  (forward) and 5’-C AGG TGC AAA CTT CCA AAT G-3’ 
(reverse), to insert the 334DY→KF335 mutations on factor VKFKF as a template (bold 
underlined letters identify the mutated bases).  To construct factor VKF/4A these same 
primers were used and factor VAAAA was used as the template in the PCR reaction.  
Factor V6A was constructed with the primers, 5’-GAG GAA GTC ATT TGG GCC 
GCC GCA CCT GTA ATA- 3’ (forward) and 5’-TAT TAC AGG TGC GGC GGC 
CCA AAT GAC TTC CTC-3’ (reverse), with factor VAAAA as the template in the 
PCR reaction.  The mutations were confirmed by DNA Sequencing (DNA Analysis 
Facility, Cleveland State University).  Figure 3.1 shows a schematic of the 
recombinant factor V molecules. 
3.3.3 Transient Transfection of Recombinant Factor V Molecules. 
     The COS-7L cell line will be maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum and the antibiotics streptomycin 
(100µg/ml) and penicillin (100IU/ml) in an atmosphere of 5% CO2, 95% air, and 
370C.  The purified wild type, factor V3K, factor VKF/4A, and factor V6A plasmids were 
transfected into the COS-7L cells with fugene 6 (Roche Diagnostics) according to the 
manufacturer’s instructions.  In short, 4µg of DNA, 300µL of serum free media, and 
27µL of fugene 6 per cell culture plate was pre-incubated for 15-45 minutes at room 
 95
temperature.  The mixture was then added drop-wise to the culture plate.  After 48 
hours of incubation, the cells will be washed twice with PBS buffer and 6ml of VP-
SPM media supplemented with 4mM L-glutamine will be added.  Following 24 hours 
the media will be harvested and fresh VP-SPM media will be added.  Harvesting of 
protein will be repeated for 3-4 consecutive days and the harvest media will be stored 
at -800C.  The harvest media will be concentrated using a Cole Parmer, Masterflex 
L/S with MW=30,000 Vivaflow 50 membrane to a volume of 5-15mLs.  Then, 2mM 
DFP will be added and the protein allowed will on ice for half an hour before 
purifying the recombinant protein. 
3.3.4 Purification of Recombinant Factor V Molecules 
     The concentrated recombinant protein was centrifuged at 5,000 rpm for 5 minutes 
to remove any cellular debris.  The protein was purified on a 2ml column of 
monoclonal antibody αhFV#1 coupled to sepharose.  The column was first 
equilibrated with TBS plus 5mM Ca2+, pH 7.40 (TBS, Ca2+) (all buffers were filtered 
before use).  The recombinant protein media was added to the column and 0.5ml 
fractions were collected.  The column was washed with 12ml of TBS, Ca2+ and eluted 
with 20mM Tris Base, 2M NH3Cl, pH 7.40.  The absorbance of the collected 
fractions was recorded at 280 nm on a HITACHI U-2000 spectrophotometer and 
clotting activity monitored cofactor activity.  Fractions containing activity were 
pooled and dialyzed against TBS, Ca2+, pH 7.40 for 2 hours at 40C.  The purified 
protein was stored at -800C in small aliquots to avoid repeated freeze thaw cycles.  
The activity and the integrity of the recombinant factor V molecules were confirmed 
 96
by clotting assays using factor V deficient plasma and western blotting with 
monoclonal and polyclonal antibodies. 
3.3.5 Determination of Factor Va Clotting Activity of the Recombinant 
Molecules 
     The cofactor activity of the recombinant molecules was measured in a clotting 
assay using factor V-deficient plasma following activation of the cofactor molecules 
by thrombin (10min, 37ºC).  The values were measured on a ST art 4 Analyzer 
Coagulation Instrument (Diagnostica Stago, Parisippany, NJ) and the values were 
standardized to the percentage of control.  A linear semi-log graph was created using 
known concentrations of plasma factor Va as a control and the specific activity of 
each recombinant factor Va molecule was calculated (units/mg). 
3.3.6 Gel Electrophoresis and Western Blotting 
     Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analyses 
were carried out using 4-12% gradient gels or 9.5% gels following reduction with 2% 
β-mercaptoethanol according to the methods of Laemmli (1970).  The protein was 
transferred to polyvinylidene difluoride (PVDF) membranes following the described 
method of Towbin et al. (1979).  Factor Va heavy and light chains were probed with 
the appropriate antibodies and visualized with chemiluminescence; or, the protein 
was visualized by staining with Coomassie Brilliant Blue R-250, followed by 
destaining in a solution of methanol, acetic acid, and water. 
3.3.7 Factor Va Titrations 
     The ability of the recombinant factor V molecules to assemble in the 
prothrombinase complex and bind to the enzyme was measured in a discontinuous 
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assay described in detail elsewhere (15).  In short, all recombinant factor V molecules 
were activated with thrombin (10 min. at 370C).  Reaction mixtures contained PCPS 
vesicles (20µM), DAPA (3µM), factor Xa (varying concentration), and recombinant 
factor V species in Reaction Buffer (varying concentration) HEPES, 0.15M NaCl, 
50nM CaCl2, 0.01% Tween-20, pH 7.40).  For the practical calculation of the KD 
between the factor Va molecules and factor Xa, assays were performed in the 
presence of limiting factor Xa concentration (15pM) and varying concentrations of 
the recombinant factor Va species (25pM to 5nM).  A zero point was taken and the 
reaction was started upon the addition of 1.4µM prothrombin.  At the following time 
points 10, 20, 30, and 60 seconds, aliquots of the reaction mixture were removed and 
diluted in 2 volumes quench solution (20nM HEPES, 0.15M NaCl, 50nM EDTA, 
0.1% PEG 8000, pH 7.40) in a 96-well sample plate.  The rate of thrombin generation 
was measured using a chromogenic substrate, Spectrozyme TH (0.4nM), which 
probes for thrombin generation.  The initial rate of thrombin generation was analyzed 
with Prizm (GraphPad) software. 
3.3.8 Prothrombin Titrations 
     Next, the capability of the recombinant factor Va molecules to assemble into the 
prothrombinase complex, bind to the substrate prothrombin, and the rate of catalytic 
efficiency was measured.  For the determination of the kinetic constants of 
prothrombinase assembly, Km and kcat, experiments were executed with a limiting 
amount of factor Xa (5 pM) in the presence of a fixed amount of the various 
recombinant factor Va molecules at their saturation concentrations (10 nM to 20 nM), 
PCPS vesicles (20 µM), and DAPA (3 µM) in Reaction Buffer.  A zero point was 
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taken and the reaction was started with varying amounts of the substrate prothrombin 
(25 nM to 4 µM).  Aliquots were removed at the time points 20, 40, 60, and 120 
seconds and the reaction was stopped in 2 volumes Quench Buffer.  The rate of 
thrombin generation was measured using a chromogenic substrate, Spectrozyme TH 
(0.4 nM), which probes for thrombin generation.  The initial rate of thrombin 
generation was analyzed with Prizm (GraphPad) software. 
3.3.9 Calculation of Factor Xa Saturation by Recombinant Factor Va Molecules 
     To order to compare prothrombinase function assembled in the presence of the 
various mutant recombinant molecules we have first calculated the kd of each species 
for factor Va as described above by titrating a fixed amount of factor Xa with 
increased concentrations of factor Va as described above.  Once the value of the kd of 
the interaction of each species of factor Va with factor Xa was determined, the 
amount of recombinant factor Va required to completely saturate factor Xa and 
provide similar amount of enzyme (prothrombinase) when using various factor Va 
recombinant molecules (between 95% - >99% saturation) can be calculate as 
abundantly described in the literature (15).  Briefly, the kd for the factor Va-factor Xa 
interaction is given by the equation: 
[ ] [ ]
[ ]XaVa
XaVaK FFd •
⋅=  (1) 
The maximum amount of factor Xa saturated with factor Va formed under the 
conditions used can be verified by replacing in equation (1) [Va]F and [Xa]F by: 
[ ]Va F = [ ]Va T - [ ]XaVa •  (2) 
[ ]Xa F = [ ]Xa T - [ ]XaVa •  (3) 
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where, [Va]F and [Xa]F are the concentrations of free factor Va and factor Xa, while 
[Va]T and [Xa]T are the total concentrations of factor Va and factor Xa respectively.  
The final concentration of factor Xa within the mixture was 1nM and the maximum 
amount of factor Xa saturated with factor Va formed under the above conditions was 
extrapolated from the following equation directly.   
[ ] [ ][ ] [ ][ ] [ ][ ] [ ] [ ][ ]
2
42 TTdTTdTT
bound
XaVanKXaVanKXaVan
Xa
⋅⋅⋅−++⋅−++⋅=
 (4) 
with the Kd for the bimolecular interaction between factor Va and factor Va on a 
phospholipid surface calculated from the functional titration described above and the 
concentration of [Va]T modified as appropriate (53).  Throughout all experiments the 
assumption was n  = moles of factor Xa bound/mole of factor Va at saturation; 
throughout this study n  = 1; the stoichiometry of the factor Va-factor Xa interaction 
was fixed at 1. 
3.3.10 Calculation of Additive Effect of the Quadruple or Sextuplet Mutations on 
Prothrombinase Function 
     The change in transition-state stabilization free energy, which measures the effect 
of the mutations in the cofactor of the prothrombinase complex have on the catalytic 
site of the enzyme, was calculated for the double mutants as extensively described 
previously (A6).  In brief, the perturbation to the function of prothrombinase 
assembled with wild type factor Va (state A) caused by a mutation in factor Va (state 
B) affecting the transition state can be defined in general as follows: 
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ABB GGG ∆−∆=∆∆   (Eq. 1) 
and since prothrombinase activity (assembled with each of the recombinant factor Va 
proteins) is being measured against the same substrate (prothrombin), the transition-
state stabilization free energy (∆∆G‡A→B) during catalysis induced by a mutation in 
factor Va can be determined from the following equation: 
∆∆G‡A→B = - RT ln [(kcat/Km)B/(kcat/Km)A] (Eq. 2) 
where R is the universal gas constant (2 cal•K-1•mol-1), T is the absolute temperature 
(298 K in the experiments presented here), kcat is the turnover number, and Km is the 
Michaelis Menten constant of the reaction.  Once calculated, these values can be used 
to determine ∆∆Gint, which reflects the exchange in free energy between the amino 
acids side chains manipulated in this study (D334K or A, Y335F or A, D695K or A, 
Y696F or A, D697K or A, and Y698F or A) by the following equation: 
∆∆Gint = ∆∆GA→B/C – (∆∆GA→B + ∆∆GA→C)    (Eq. 3) 
A positive value of ∆∆Gint indicates that the interaction of these amino acid side 
chains reduce the catalytic efficiency of prothrombinase, negative value demonstrates 
that the mutations are better for prothrombinase, resulting in an increase in the 
catalytic efficiency of the enzyme.  A value of zero would indicate no effect. 
 3.3.10 Prothrombin Activation Measured by Gel Electrophoresis  
 
     Prothrombin will be incubated in a reaction mixture containing the following: 
20µM PCPS, 50µM DAPA, and 10nM of factor VaWT and 20nM of factor Va3K, 
factor VaKF/4A, and factor Va6A(activated with thrombin) in TBS, Ca2+.  A zero point 
was taken and the addition of 1 nM factor Xa marked the start of the reaction.  
Aliquots of the reaction mixture will be removed at selected time point  (0:20, 0:40, 
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1:00, 1:20, 1:40, 2:00, 2:20, 2:40, 3:00, 3:20, 3:40, 4:00, 5:00, 6:00, 10:00, 20:00, 
30:00 and 60:00 minutes) and added to two volumes 0.2M glacial acetic acid.  The 
samples will be dried in a centrivap and reconstituted in 0.1M Tris base, pH 6.8, 1% 
SDS, 1% β-mercaptoethanol and heated for exactly 75 seconds at 950C.  A total of 
5µg of total protein will be loaded per lane and analyzed on 9.5% SDS-PAGE 
followed by staining with Coomassie Blue.  
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2.4 Results 
2.4.1 Transient Expression and Activation of Recombinant Factor V Molecules 
     In order to further assess the importance of residues from the heavy chain of factor 
Va, specifically, amino acid residues 334-335 and 695-698, recombinant protein 
technology was used.  Mutant recombinant factor Va molecules, factor V3K (D334K, 
Y334F, D695K, Y696F, D697K, and Y698F), factor VKF/4A (D334K, Y335F, D695A, 
Y696A, D697A, and Y698A), and factor V6A (D334A, Y335A, D695A, Y696A, 
D697A, and D698A) were prepared.  Recombinant factor VWT and the mutants were 
expressed in COS-7 cells, and the resulting proteins were purified to homogeneity on 
a monoclonal antibody column specific to factor V. 
     First, the recombinant molecules were assessed for their clotting activity in a two-
stage clotting activity assay and the results are shown in Table 3.1.  Thrombin 
activation of factor VWT resulted in a cofactor with similar clotting activity 
(597U/mg) to plasma factor Va (data not shown).  The mutant recombinant factor Va 
molecules displayed reduced clotting activities compared to the wild type molecule.  
Factor Va6A has a 4-fold decrease in the clotting activity (149U/mg), factor VaKF/4A 
has a 6.5-fold reduction in the clotting activity (93.7U/mg), and factor Va3K is most 
impaired in its’ clotting activity with a 20- fold decrease (28.6U/mg).  The results 
demonstrate that mutation of the amino acid motif DY→KF has a more detrimental 
effect that mutation to alanine residues. 
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Table 3.1 Clotting Times and Activities of Recombinant Factor Va Molecules.  
The 2-stage clotting time and clotting activity were determined as outlined by the 
“Experimental Procedures”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factor Va 
Species 
2-Stage Clotting 
Time 
Activity 
(U/mg) 
Factor VaWT 18.63±0.81 597 
Factor Va3K 47.58±0.93 28.6 
Factor VaKF/4A 35.76±2.13 93.7 
Factor Va6A 31.8±0.75 149 
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3.4.2 Kinetic Analysis of Recombinant Factor Va Molecules 
     Next, we examined the capability of the recombinant factor Va molecules to 
assemble in the prothrombinase complex using an assay with purified reagents and a 
chromogenic substrate to probe for thrombin generation.  The assay was performed 
with conditions of limiting factor Xa concentrations, any deficiency in the ability of 
the recombinant molecules to act as a cofactor in the enzymatic prothrombinase 
complex, will reflect the ability of the factor V species to properly bind the enzyme 
and activate prothrombin..  Figure 3.2 and Table 3.2 show the results of the kinetic 
studies.  The data demonstrate that under the experimental conditions factor VaWT has 
the same affinity for the enzyme, factor Xa, as the plasma factor Va counterpart (kd = 
~0.2nM).  Conversely, the recombinant factor Va molecules, factor Va3K, factor 
VaKF/4A, and factor Va6A were impaired in their ability to productively bind the 
enzyme having, dissociation constants with 7-fold increase for factor Va3K and 10-
fold increase for factor VaKF/4A and factor Va6A.  These results are interesting because 
when amino acid residues 334-335 and 695-698 are mutated separately, they do not 
display deviations in their binding constants.  Therefore, it can be concluded that in 
order to have an effect on the affinity for factor Xa, both amino acid regions are 
required. 
          We further evaluated the effect of the mutations in the recombinant factor Va 
molecules to assemble in the prothrombinase complex and activate prothrombin using 
kinetic experiments designed to determine the Km  and kcat values for prothrombinase  
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Figure 3.2  Factor Va Titrations.  Thrombin generation experiments were carried 
out as described under “Experimental Procedures”.  Prothrombinase complex 
assembled with varying concentrations (30 pM to 5 nM) of purified recombinant 
factor VaWT (closed squares), purified factor Va3K (filled triangles), purified factor 
VaKF/4A (closed inverted triangle), and purified factor Va6A (filled circles).   The solid 
lines represent a nonlinear regression fit of the data using Prizm GraphPad software 
for a one binding site model.  Titrations were performed in triplicate with at least four 
different preparations of purified and partially purified protein. 
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function.  The experiments were performed in the presence of limiting amounts of 
factor Xa (5-10pM) and the concentration of the cofactor was kept constant (10-
20nM) while the substrate concentration was varied (25nM to 4µM) and the results 
are displayed in Figure 3.4 and Table 3.2.  Under the experimental conditions 
employed, factor VaWT displays an affinity for the substrate, prothrombin, similar to 
the plasma counterpart.  In contrast the results with the previous experiments showing 
the decreased affinity for the enzyme, the results of the prothrombin titrations show 
similar affinities for prothrombin.  Next, the catalytic efficiencies were compared in 
Figure3.5.  These kinetic studies show that factor Va3K, factor VaKF/4A, and factor 
Va6A have a 6.5, 1.7, and 1.4-fold reduced catalytic efficiency compared to factor 
VaWT.  Conversely, when amino acid region 695-698 alone is mutated, factor VaKFKF 
and factor VaAAAA have 1.4 and 1.2-fold increased catalytic efficiency compared to 
the wild type molecule.  This increased catalytic efficiency can be explained by 
sustained meizothrombin accumulation (data not shown).  Subsequently, the substrate 
specificities (kcat/Km) were compared between the recombinant factor Va molecules 
and the results are shown in Figure 3.6.  These results demonstrate that, similar to the 
comparisons of kcat values, the substrate specificities are also reduced in the 
recombinant factor Va molecules, factor Va3K (4.5-fold reduced value), factor VaKF/4A 
(2-fold reduced value), and factor Va6A (1.6-fold reduced value).  While the sextuplet 
mutants display decreased substrate affinity, the quadruple 695-698 mutants display 
an increase; factor VaKFKF and factor Va4A both have approximately a 1.5-fold 
increase in the specificity.  
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Figure 3.3 Prothrombin Titrations.  Thrombin generation experiments were carried 
out as described under “Experimental Procedures” by varying the substrate 
concentration (25 nM to 4 µM) with 10 pM of factor Xa saturated with the factor Va 
species.  Prothrombinase complex assembled with recombinant purified wild type 
factor Va (filled squares), ,purified factor Va3K (filled triangles),purified factor 
VaKF/4A (filled inverted triangles), and  purified factor Va6A (closed circles).  The data 
shown are the average of five different titrations performed in triplicate with at least 
four different preparations of purified and partially purified proteins.   
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Table 3.2 Kinetic Constants of Recombinant Factor Va Molecules.  The 
dissociation constants of recombinant factor Va species for plasma derived factor Xa 
were calculated at limiting concentrations of the enzyme as described in 
“Experimental Procedures”.  The Km constants were determined at described in 
“Experimental Procedures” using limiting amounts of the enzyme and varying 
concentrations of substrate. 
 
 
 
 
 
 
 
0.441 2.33 Factor Va6A 
0.458 2.46 Factor VaKF/4A 
0.3032 1.76 Factor Va3K 
0.164 0.238 Factor VaWT 
Km (µM) Kd (nM) Factor Va 
Species 
 109
 
 
 
 
 
 
 
Figure 3.4 Comparison of kcat Values.  The values of kcat were determined using the 
kd’s and the quadratic equation to determine the saturation concentration of the 
various recombinant factor Va species. 
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Figure 3.5 Comparisons of Second Order Rate Constants.  The second order rate 
constants were determined by dividing the kcat by the Km. 
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3.4.4 Additive Effect of Mutations in the Heavy Chain of Factor Va on 
Prothrombinase Function 
     If there is a disturbance in the interaction between factor Xa and factor Va within 
the prothrombinase complex caused by inserting a mutation it could impact the 
stability of the catalytic site of the enzyme and can be determined by measuring the 
transition state stabilization free energy of prothrombin activation as describe in 
‘Experimental Procedures’.  To determine if the two separate mutation sites on the 
heavy chain of factor Va interact with each other to affect the catalytic site of factor 
Xa, thermodynamic cycles were created and the exchange in free energy between the 
side chains of amino acids residues under investigation (334DY335 and 695DYDY698) 
was calculated and the results are shown in Figure 3.7.  Factor Va3K has a ∆∆Gint 
value of +1.722 indicating the DY→KF substitution of amino acid residues 334-335 
and 695-698 do not have an additive effect but are disruptive in nature which results 
in a slower rate of prothrombin catalysis evidenced by kinetic and gel electrophoretic 
analysis.  On the other hand the substitution of DYDY→AAAA in recombinant 
proteins factor VaKF.4A and factor Va6A do have slightly negative values for ∆∆Gint (-
0.313 and -0.760, respectively) implying that the alanine substitutions are not 
detrimental to cofactor activity.  In conclusion, these mutations appear to create a 
molecule that is a better cofactor for factor Xa. All together these data imply that the 
interaction of factor Va heavy chain with factor Xa and prothrombin are fundamental 
for efficient of prothrombin to thrombin. 
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Figure 3.6 Additive Effect of Recombinant Proteins on Prothrombin Catalysis.  
∆∆Gint  is the enery of interaction between the side chains of  334DY335 and 
695DYDY698 of factor Va heavy chain and was calculated as described under 
“Experimental Procedures”. 
 
 
 
 
 
 
 
 -0.276 kcal/mol
Factor VaWT Factor VaKF 
Factor VaKFKF Factor Va3K 
+1.06 kcal/mol
+0.856 kcal/mol
+0.205  +1.722kcal/mol
Factor Va3K ∆∆Gint  = +1.722 
Factor VaKF/4A  ∆∆Gint  = -0.313 kcal/mol 
Factor Va6A     ∆∆Gint  = -0.760 kcal/mol 
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3.4.5 Prothrombin Activation By Prothrombinase Assembled with Factor VaWT, 
Factor Va3K, Factor VaKF/4A, and Factor Va6A      
     To test the ability of the recombinant factor Va molecules to successfully assemble 
in the prothrombinase complex and activate prothrombin gel electrophoresis was 
used.  The cofactor molecules were allowed to pre-incubate with prothrombin in the 
presence of a membrane surface and calcium and factor Xa was added to start the 
reaction.  The results in Figure 3.8 demonstrate that the prothrombin activation 
schemes for all cofactor molecules are similar and proceed through the 
meizothrombin pathway displayed by the presence of fragment 1.2A of prothrombin 
which is the result of initial cleave at Arg320.  The mutant cofactor molecules have a 
slower rate of prothrombin and fragment 1.2A disappearance.  These results indicate 
that factor Va3K, factor VaKF/4A, and factor Va6A have a slower rate of cleavage at 
Arg271 and the presence of the intermediate meizothrombin is sustained longer than 
compared to the wild type molecule. 
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Figure 3.7 Prothrombin Activation by Prothrombinase Assembled with the 
Recombinant Factor Va Molecules.  Recombinant factor Va molecules, factor 
VaWT,   factor Va3F, factor VaKF/4A and factor Va6A were incubated with prothrombin, 
PCPS vesicles, and DAPA as detailed in the “Experimental Procedures” section at a 
final concentration of 10 nM for the factor VaWT and 20 nM for the mutant molecules.  
Factor Xa was added to start the reaction to a final concentration of 1nM.  Aliquots 
were withdrawn at given time intervals and treated as described in the “Experimental 
Procedures”.  The legends to the right of the gels indicate the prothrombin activation 
fragments: II (prothrombin), F1•2A (Fragment 1•2-A chain), F1•2 (fragment 1•2), 
and B (B chain of thrombin), Experiments were performed with least three 
preparations of purified proteins and one representative gel is shown. 
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3.5 Discussion 
      The mechanism by which the cofactor, factor Va, improves the catalytic 
efficiency of the enzyme, factor Xa, is not well understood.  There is an agreement in 
the literature that in order for prothrombin to bind to the prothrombinase complex, an 
exosite on factor Xa and/or factor Va must be expressed.  Presently we have shown 
that amino acid residues 334-335 together with 695-698 of the factor Va heavy chain 
are imperative for factor Xa to efficiently convert prothrombin to thrombin because of 
diminished productive collisions due to defective interaction with both factor Xa and 
prothrombin.  We have previously demonstrated that residues 334DY335 are crucial for 
optimum re-arrangement of enzyme and substrate required for efficient catalysis of 
prothrombin by prothrombinase.  Mutation of these residues results in a cofactor with 
impaired catalytic efficiency of prothrombin activation compared to wild type factor 
Va in a prothrombinase assay with purified reagents and a chromogenic substrate.  
Our laboratory has also identified factor Xa binding sites on the central portion of the 
factor Va heavy chain.  Mutation of amino acid residues 323 and 324 together with 
330 and 331 results in a recombinant molecule, factor VaFF/MI, that is unable to 
competently activate prothrombin to thrombin through the meizothrombin pathway 
(15).  Our laboratory has also established that residues from the COOH-terminus of 
factor Va heavy chain are involved in cofactor function.  In order to establish if 
residues 334-335 and 695-698 allosterically work together recombinant protein 
technology was used.  The obtained results demonstrate that only when these residues 
are combined they have a remarkable effect on cofactor activity.  Factor Va3K has a 
nearly 7-fold reduction in the catalytic efficiency compared to factor VaWT, while 
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when the amino acid regions are mutated by themselves they have a 1.6-fold decrease 
and a 1.2-fold increase for factor VaKF and factor Va3K, respectively.  These results 
support our hypothesis that amino acids 334-335 and 695-698 are on the surface of 
the factor Va heavy chain and they act in concert for optimal cofactor function and 
prothrombin activation. 
     It has been previously demonstrated that the role of factor Va in the 
prothrombinase complex is to localize factor Xa on the membrane surface and that 
factor Va-factor Xa binding does not induce a change in the catalytic site of the 
enzyme toward small synthetic substrates.  It has, therefore, been proposed that the 
factor Va dependent increase in catalytic efficiency of prothrombinase is owed to the 
stabilization of the prothrombin binding site (16).  Our data support this hypothesis 
because multiple mutations in the heavy chain of the cofactor result in a molecule that 
has less productive collisions between the enzyme and substrate, therefore resulting in 
slower prothrombin production. 
     It has been established that effective prothrombin activation is a result of 
proexosite-1 on prothrombin interacting with a site on the prothrombinase complex 
(7).  Further studies have shown that a proexosite-1 specific peptide ligand taken form 
the C-terminal domain of the leech inhibitor, hirudin, is able to inhibit activation of 
prothrombin in the presence of, but not in the absence, factor Va.  The C-terminus of 
the factor Va heavy chain has a homologous domain to the hirudin peptide, 
suggesting that it is factor Va in the prothrombinase complex that may provide a 
binding site for proexosite-1 of prothrombin (8).  Our laboratory has demonstrated 
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that a peptide of factor Va, DYDYQ, with a hirudin-like sequence results in the 
inhibition of initial cleavage of prothrombin at Arg320 by the enzyme (17).   
     There are conflicting results in the literature regarding the importance of the 
COOH-terminus of the factor Va heavy chain.  One group has published that the C-
terminal region of factor Va heavy chain does not contribute to the increased catalytic 
function of prothrombin activation by prothrombinase (18).  Their results demonstrate 
that recombinant molecules with regions of the carboxyl-terminal of factor Va heavy 
chain, factor Va709 (des710-1545), factor Va699 (des700-1545), and factor Va692 
(des693-1545), and factor Va678 (des679-1545), exhibited similar clotting activities to 
plasma-derived factor Va and had unaltered Km and kcat values.  However, closer 
interpretation of the published data may indicate some points were overlooked; factor 
Va709, factor Va699, factor Va692 and factor Va678 display kcat values 1.2-fold, 1.4-fold, 
1.3-fold, and 1.5-fold increased values compared to the recombinant factor VaWT.  
These results are in agreement with our kinetic data with factor VaKFKF that also has a 
1.2-fold increased kcat value.  Our interpretation of these results differ in that we feel 
this is a significant difference in cofactor function; this observation is further backed 
by experiments using gel electrophoresis to analyze prothrombin activation.  We have 
shown that recombinant factor VaKFKF displays sustained meizothrombin formation 
during a one hour time course of prothrombin activation (data not shown). 
     Overall, our data clearly demonstrate that amino acids from the heavy chain of 
factor Va, namely residues 334-335 and 695-698, are fundamental to cofactor 
function and most favorable for  prothrombin activation. 
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CHAPTER IV 
APC INACTIVATION OF FACTOR Va 
 
 
4.1 Abstract 
     The coagulation cascade results in the production of thrombin which will aide in the 
formation of the fibrin plug to stop bleeding.  The prothrombinase complex, composed of 
the enzyme factor Xa, the cofactor factor Va, and the substrate prothrombin associated on 
a cell surface in the presence of divalent metal ions, catalyzes the activation of 
prothrombin to thrombin 300,000-fold more effectively than the enzyme alone.  Once 
enough thrombin is produced, it then participates in the down-regulation of the cascade 
by activating protein C to its active form, activated protein C (APC).  APC down 
regulates the coagulation cascade by inactivating the protein cofactors, factor Va and 
factor VIIIa, by proteolysis.  APC inactivates factor Va following proteolytic cleavages at 
Arg306, Arg506, and Arg679.  Individuals with a single amino acid substitution at 
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residue 1691 (G →A) results in a factor V molecule with Arg506 → Gln substitution 
(designated factor VLEIDEN).   These individuals have delayed inactivation of factor Va.  
The delayed inactivation is due to the inability of factor VaLEIDEN to get cleaved at 
Arg506 and as a result cleavage at Arg306 is retarded.  In order to analyze the effect of 
APC inactivation on prothrombin activation, a recombinant protein scheme was used to 
create mutant cofactor molecules with the APC cleavage sites on factor V/Va mutated.  
Our data demonstrate that APC cleavage at Arg306 are not equal in the procofactor and 
active cofactor protein, with greatly increased clotting times with inactivation of the 
procofactor and decreased affinity for the enzyme and substrate in the prothrombinase 
complex.  We also validate in the absence of APC inactivation cleavage sites Arg306 and 
Arg506 the procofactor and active cofactor are unable to be proteolyitcally inactivated by 
APC in the presence of a membrane surface. 
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4.2 Introduction 
     The coagulation cascade culminates in the production of thrombin from prothrombin 
by the prothrombinase complex, i.e. factor Xa, factor Va, Ca2+, on a membrane surface.  
It has been well established in the literature that the cofactor, factor Va, is of 
physiological importance, in that is increases the catalytic efficiency of prothrombin 
activation by the enzyme, factor Xa, by five orders of magnitude.  Once enough thrombin 
is produced to stop bleeding when there is an injury to the vasculature, down regulation 
of the coagulation cascade begins.  Thrombin serves two roles in hemostasis, as a 
coagulant (to promote clotting by aiding in the formation of the fibrin plug) and as an 
anti-coagulant (to start the down-regulation of the coagulation cascade by a positive 
feedback mechanism).  The anti-coagulant function of thrombin is to activate protein C 
(PC), a zymogen to a vitamin K-dependent serine protease, one of the key components of 
the natural anti-coagulant pathway.   
     The protein Case complex is composed of the enzyme, activated protein C (APC) and 
the cofactor, protein S (PS), in the presence of a membrane surface.  This complex is 
imperative to the anticoagulant mechanism of the blood coagulation cascade.  The 
cofactor function of protein S are weak in purified systems, only enhancing the APC 
inactivation of factor Va by a factor of two (1).  Once formed, protein Case can inactivate 
the cofactors to the intrinsic and prothrombinase complexes, factor VIIIa and factor Va, 
respectively.  APC cleaves three peptide bonds in the A1-A2 domains of factor Va, at 
Arg306, Arg506, and Arg679 and it cleaves factor VIIIa at two peptide bonds, Arg336 and 
Arg562.  However, APC cleavage does not appear to be essential to inactivation because 
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factor VIIIa inactivation occurs spontaneously following the dissociation of the A2 
domain (2-4).   
     Extensive studies have been performed to determine the molecular mechanism of APC 
inactivation of factor Va in the prothrombinase complex.  It has been demonstrated that 
not all factor Va inactivating cleavages are equal.  The first cleavage at Arg506 is 
kinetically favored and results in a molecule with decreased cofactor activity (5-7).  It is 
also known that cleavage at Arg506 in factor Va is necessary for cleavage at Arg306.  It is 
cleavage at Arg306 that leads to full loss of cofactor function and the dissociation of the 
A2 domain from the rest of the molecule (8, 9).  The last inactivation cleavage at Arg679 
has not been extensively characterized.  In addition, APC can also cleave the pro-cofactor 
in the presence of a membrane surface at residues Arg306, Arg506, Arg679, and Lys994.  It is 
the first cleavage at Arg306 that is the inactivating cleavage (10).   
     It is known that complete inactivation of factor Va by APC occurs in the presence of a 
membrane surface and requires all three cleavages at Arg306, Arg506, and Arg679 (5, 11).  
However, factor Va can be cleaved in the absence of a membrane surface only at residues 
Arg506 and Arg679.  It has been demonstrated that a factor Va molecule that has been 
cleaved at these two positions maintains ~80% of its cofactor activity in a 
prothrombinase assay under saturating conditions of factor Xa.  On the other hand, when 
tested in a clotting assay, the same molecule retains only ~40% of cofactor activity.  It 
has also been shown that factor Va cleaved at positions Arg506 and Arg679 has a reduced 
affinity for both factor Xa and prothrombin (12-14).  Conversely, when a membrane 
surface is present, cleavage at Arg306 is possible, and this cleavage is coupled to the 
complete loss of cofactor activity no matter what assay is used. 
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     The importance of the first inactivation cleavage of factor Va is clear in patients with 
APC resistance that have a molecular defect that has been linked to a single point 
mutation of Arg506 to Gln (designated factor VLEIDEN (5).  The factor VLEIDEN phenotype is 
present in 5% of the western countries (15) and is a major risk factor for venous 
thrombosis in patients with this mutation (16).  Because factor VLEIDEN does not have the 
Arg506 cleavage site, APC inactivation is delayed.  This delay in inactivation is due to 
slower cleavage at Arg306, indicating that the cleavage at Arg506 is mandatory for 
successful inactivation of the cofactor (17).  These data suggest that both cleavages at 
Arg306 and Arg506 are essential for full inactivation of factor Va.   
     In addition, two new mutations in the factor V gene were recently reported, with 
mutations Arg306 to Gly (factor V Hong Kong) and Arg306 to Thr (factor V Cambridge) 
(18, 19).  Factor V Cambridge was discovered in a patient that had thrombosis with 
unexplained resistance to APC.  The factor V Hong Kong mutation was found in two 
Chinese patients with venous thrombosis.  It was suspected that a mutation at Arg306 
would cause a severe thrombotic state, since it is cleavage at Arg306 in factor Va by APC 
that causes complete inactivation of the cofactor.  However, neither factor V Cambridge 
nor factor V Hong Kong appear to be related to patients with a increased risk for 
thrombosis (20, 21).  Further evidence is needed to further elucidate the mechanism of 
these mutations in factor V. 
     The present study was undertaken to elucidate the molecular mechanism of factor V 
/Va inactivation by APC in the presence of a membrane surface.  Through recombinant 
protein technology, factor V molecules were created with the inactivating cleavage sites 
of factor Va, or combination of cleavage sites, mutated to determine which products of 
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the individual inactivating cleavage sites of factor Va by APC will produce intermediates 
that have different effects on factor Va cofactor assembly and function. 
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4.3 Experimental Procedures  
4.3.1 Materials and Reagents 
     Diisopropyl-fluorophosphate (DFP), O-phenylenediamine (OPD)-dihydrochloride, N- 
[2-Hydroxyethyl] piperazine-N’-2-ethanesufonic acid (Hepes), Trizma (Tris base), and 
Coomassie Blue R-250, were purchase from Sigma (St. Louis, MO).  Factor V-deficient 
plasma is from Research Protein Inc. (Essex Junction, VT).  Secondary anti-mouse and 
anti-sheep IgG coupled to peroxidase were purchased from Southern Biotechnology 
Associates Inc. (Birmingham, AL).  L-α-phosphatidylserine (PS) and L-α-
phosphatidylcholine (PC) were from Avanti Polar Lipids (Alabaster, AL).  
Chemiluminescent reagent ECL+ and Heparin –Sepharose were from 
AmershamPharmacia Biotech Inc. (Piscataway, NJ).  Normal reference plasma and 
chromogenic substrate Spectrozyme-TH were from American Diagnostica Inc. 
(Greenwich, CT).  Thromboplastin reagent was purchased from Organon Teknika Corp.  
(Durham, NC).  Dansylarginine-N- (3-ethyl-1, 5-pentanediyl) amide (DAPA), human 
factor Xa, human thrombin, and human prothrombin were purchased from Haematologic 
Technologies Inc. (Essex Junction, VT).  Human activated protein C and factor Xa were 
purchased from Enzyme Research Laboratories (South Bend, IN).  Factor V cDNA is 
from American Type Tissue Collection (ATCC# 40515 pMT2-V, Manassas, VA).  All 
restriction enzymes were from New England Biolabs (Beverly, MA).  All molecular 
biology and tissue culture reagents, specific primers, and medium were from Gibco, 
Invitrogen Corp. (Grand Island, NY) or as indicated.  Human factor V monoclonal 
antibodies (αHFVHC#17 and αHFVLC#9) and monoclonal antibody αHFV#1 coupled to 
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Sepharose were provided by Dr. Kenneth G. Mann (Department of Biochemistry, 
University of Vermont, Burlington, VT). 
4.3.2 Construction of Recombinant Factor V Molecules 
     Recombinant factor V molecules, Factor V306, factor V506,  factor V679, factor V306/506, 
factor V306/679, factor V506/679, and factor V306/506/679 were constructed using Stratagene’s 
QuikChange® XL Site-Directed Mutagenesis Kit.  The factor V306 mutation was 
constructed with the following primers; 5’ GC CCA AAG AAA AAA ACC CAG AAT 
CTT AAG 3’ (forward) and 5’ CTT AAG ATT CTG GGT TTT TTT CTT TGG GC 
3’(reverse).  The factor V506 mutation was constructed with the following primers; 5’ GC 
AGA TCC CTG GAC CAG CAA GGA ATA CAG AGG GCA GC 3’ (forward) and 5’ 
CG TGC CCT CTG TAT TCC TTG CTG GTC CAG GGA TCT GC 3’ (reverse).  The 
factor V679 mutation was constructed with the following primers; 5’ CT ACA GTC ATG 
GCT ACA CAG AAA ATG CAT GAT CGT TTA GAA CC 3’ (forward) and 5’ GG 
TTC TAA ACG ATC ATG CAT TTT CTG TGT AGC CAT GAC TGT AG 3’ (reverse).  
The bold, underlined bases indicated the mutated base pairs to insert the R → Q 
mutation.  The double and triple mutants were constructed as follows; Arg306/506 with 
Arg506 as the template using the Arg306 primers, Arg306/679 with Arg679 as the template 
with Arg306 primers, Arg506/679 with Arg679 as the template with Arg506 primers, and 
Arg306/506/679 with Arg506/679 as the template with Arg306 primers.  The mutations were 
confirmed by DNA Sequencing (DNA Analysis Facility, Cleveland State University).  
Figure 4.1 shows a schematic of the recombinant factor V molecules. 
 128
 
Figure 4.1 Schematic of Recombinant Factor V Molecules.   Scheme of mutant 
recombinant factor V molecules constructed with mutations at Arg306, Arg506, and Arg679. 
     
 
 
 
 
 
 
 
 
 
 
Recombinant Factor V Molecules  
Factor VWT   No Mutation 
Factor V306   R306 → Q 
Factor V506   R506 → Q 
Factor V679   R679 → Q 
Factor V306/506     R306 → Q, R506 → Q 
Factor V306/679   R306 → Q, R679 → Q 
Factor V506/679   R506 → Q, R679 → Q 
Factor V306/506/679  R306 → Q, R506 → Q, R679 → Q 
Arg50
6
A1NH COO
22/20,0045,00
Arg67
9
30,00
Arg30
6
Q Q Q 
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 4.3.3 Transient Transfection of Recombinant Factor V Molecules. 
     The COS-7L cell line was be maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum and the antibiotics streptomycin 
(100µg/ml) and penicillin (100IU/ml) in an atmosphere of 5% CO2, 95% air, and 370C.  
The purified wild type, factor V306, factor V506, factor V679, factor V306/506, factor V306/679, 
factor V506/679, and factor V306/506/679 plasmids were transfected into the COS-7L cells 
with fugene 6 (Roche Diagnostics) according to the manufacturer’s instructions.  In short, 
4µg of DNA, 300µL of serum free medium, and 27µL of fugene 6 per cell culture plate 
was pre-incubated for 15-45 minutes at room temperature.  The mixture was then added 
drop-wise to the culture plate.  After 48 hours of incubation, the cells were be washed 
twice with PBS buffer and 6ml of VP-SPM medium supplemented with 4mM L-
glutamine was added.  Following 24 hours the media was harvested and fresh VP-SPM 
media was added.  Harvesting of protein was repeated for 3-4 consecutive days and the 
harvest medium was stored at -800C.  The harvest medium was concentrated using a Cole 
Parmer, Masterflex L/S with MW=30,000 Vivaflow 50 membrane to a volume of 5-
15mLs.  Then, 2mM DFP was added and the protein allowed will on ice for half an hour 
before purifying the recombinant protein. 
4.3.4 Purification of Recombinant Factor V Molecules 
     The concentrated recombinant protein was centrifuged at 5,000 rpm for 5 minutes to 
remove any cellular debris.  The protein was purified on a 2ml column of monoclonal 
antibody αhFV#1 coupled to sepharose.  The column was first equilibrated with TBS plus 
5mM Ca2+, pH 7.40 (TBS, Ca2+) (all buffers were filtered before use).  The recombinant 
protein medium was added to the column and 0.5 ml fractions were collected.  The 
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column was washed with 12 ml of TBS, Ca2+ and eluted with 20 mM Tris Base, 2 M 
NH3Cl, pH 7.40.  The absorbance of the collected fractions was recorded at 280 nm on a 
HITACHI U-2000 spectrophotometer and clotting activity monitored cofactor activity.  
Fractions containing activity were pooled and dialyzed against TBS, Ca2+, pH 7.40 for 2 
hours at 40C.  The purified protein was stored at -800C in small aliquots to avoid repeated 
freeze thaw cycles.  The activity and the integrity of the recombinant factor V molecules 
were confirmed by clotting assays using factor V deficient plasma and western blotting 
with monoclonal and polyclonal antibodies. 
4.3.5 APC Inactivation of Recombinant Factor V/Va Molecules 
     The recombinant factor V molecules were inactivated with APC at a 1:50 molar ratio 
in the presence of 20µM PCPS.  The factor V species were first activated with thrombin 
to a final concentration of 1nM for 10 minutes in a 37°C water bath (designated factor 
Va).  Immediately following this incubation, the PCPS was added and allowed to 
incubate at room temperature for 5 minutes.  Then, APC was added and incubated in a 
37°C water bath for 30 minutes (designated factor Vai).  The procofactor factor V 
molecules were also inactivated with APC and PCPS without the initial thrombin 
activation (designated factor Vi). 
4.3.6 Determination of Factor Va Clotting Activity of the Recombinant Molecules 
     The cofactor activity of the recombinant molecules was measured in a clotting assay 
using factor V-deficient plasma following activation of the cofactor molecules by 
thrombin (1 nM, 10 min, 37ºC).  The clotting activities were also determined following 
inactivation of factor V/Va species with APC and PCPS.  The values were measured on a 
ST art 4 Analyzer Coagulation Instrument (Diagnostica Stago, Parisippany, NJ) and the 
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values were standardized to the percentage of control.  A linear semi-log graph was 
created using known concentrations of plasma factor Va as a control and the specific 
activity of each recombinant factor Va molecule was calculated (units/mg). 
4.3.7 Gel Electrophoresis and Western Blotting 
     Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analyses 
were carried out using 5-15% gradient gels or 9.5% gels following reduction with 2% β-
mercaptoethanol according to the methods of Laemmli (1970).  The protein was 
transferred to polyvinylidene difluoride (PVDF) membranes following the described 
method of Towbin et al. (1979).  Factor Va heavy chain and heavy chain inactivation 
fragments were probed with the appropriate antibody and visualized with 
chemiluminescence. 
4.3.8 Factor Va Titrations 
     The ability of the recombinant factor V molecules to assemble in the prothrombinase 
complex and bind to the enzyme was measured in a discontinuous assay described in 
detail elsewhere.  In short, recombinant factor V molecules were activated with thrombin 
(1 nM, 10 min at 370C) followed by inactivation with APC/PCPS, or inactivation alone.  
Reaction mixtures contained PCPS vesicles (20µM), DAPA (3µM), factor Xa (varying 
concentration), and recombinant factor Va, factor Vai, and factor Vi species in Reaction 
Buffer (varying concentration) HEPES, 0.15M NaCl, 50nM CaCl2, 0.01% Tween-20, pH 
7.40).  For the practical calculation of the KD between the factor Va, factor Vai, and 
factor Vi molecules and factor Xa, assays were performed in the presence of limiting 
factor Xa concentration (15pM) and varying concentrations of the recombinant factor Va, 
factor Vai, and factor Vi species (25pM to 5nM).  A zero point was taken and the reaction 
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was started upon the addition of 1.4µM prothrombin.  At the following time points 10, 
20, 30, and 60 seconds, aliquots of the reaction mixture were removed and diluted in 2 
volumes quench solution (20nM HEPES, 0.15M NaCl, 50nM EDTA, 0.1% PEG 8000, 
pH 7.40) in a 96-well sample plate.  The rate of thrombin generation was measured using 
a chromogenic substrate, Spectrozyme TH (0.4nM), which probes for thrombin 
generation.  The initial rate of thrombin generation was analyzed with Prizm (GraphPad) 
software. 
4.3.9 Prothrombin Titrations 
     Next, the capability of the recombinant factor Va, factor Vai, and factor Vi molecules 
to assemble into the prothrombinase complex, bind to the substrate prothrombin, and the 
rate of catalytic efficiency was measured.  For the determination of the kinetic constants 
of prothrombinase assembly, Km and kcat, experiments were executed with a limiting 
amount of factor Xa (5pM) in the presence of a fixed amount of the various recombinant 
factor Va, factor Vai, and factor Vi molecules (10nM), PCPS vesicles (20µM), and 
DAPA (3µM) in Reaction Buffer.  A zero point was taken and the reaction was started 
with varying amounts of the substrate prothrombin (25nM to 4µM).  Aliquots were 
removed at the time points 20, 40, 60, and 120 seconds and the reaction was stopped in 2 
volumes Quench Buffer.  The rate of thrombin generation was measured using a 
chromogenic substrate, Spectrozyme TH (0.4nM), which probes for thrombin generation.  
The initial rate of thrombin generation was analyzed with Prizm (GraphPad) software. 
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4.4 Results 
4.4.1 Transient Expression of Recombinant Factor V Molecules 
     In order to examine the molecular mechanism of the consequences of the individual 
inactivating cleavages of factor V/Va by APC in the presence of a membrane surface, 
recombinant factor V molecules were constructed with R → Q mutation at the APC 
cleavage sites; factor V306 (R306Q), factor V506 (R506Q), factor V679 (R679Q), factor 
V306/506 (R306Q and R506Q), factor V306/679 (R306Q and R679Q), factor V506/679 (R506Q 
and R679Q), and factor V306/506/679 (R306Q, R506Q, and R679Q).  Upon transient 
transfection and purification of the recombinant factor V molecules, we discovered the 
recombinant proteins containing the mutation at amino acid residue 679 did not express 
as well as the other recombinant molecules.  In fact, recombinant molecules with residue 
679 mutated expressed an average of 50 times lower than the other molecules as seen in 
Table 4.1.  Factor VWT, factor V306, factor V506, and factor V306/506 expressed a total of 35 
to 75µg per 10 cell culture plates transiently transfected.  On the other hand, recombinant 
factor V679, factor V306/679, factor V506/679, and factor V306/506/679 did not express over a 
total of one µg of protein, even when up to 40 cell culture plates were transfected.  For 
the practical purposes of this investigation we, therefore, only used recombinant factor V 
molecules factor VWT, factor V306, factor V506, and factor V306/506. 
4.4.2 Western Blot Analysis of APC Inactivation of Recombinant Factor V/Va 
Molecules 
     To investigate the APC inactivation fragments of the recombinant factor V/Va 
molecules, Western Blot analysis was utilized with a monoclonal antibody specific to the 
heavy chain of factor Va and the results are shown in Figure 4.2.  All recombinant factor 
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0.875 Factor V679 (any factor V with 
679 mutation) 
74.40 Factor V306/506 
37.28 Factor V506 
40.06 Factor V306 
34.85 Factor VWT 
Average Total Recombinant 
Protein Produced/Transfection 
(µg)
Recombinant Factor V  
Species 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
Table 4.1 Expression of Recombinant Factor V Molecules.  Average total protein 
transiently expressed in COS7 cells for each of the mutant recombinant factor V 
molecules.  
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molecules activated with thrombin display complete activation and the appearance of the 
heavy chain of the cofactor, Mr 105,000 (factor VaWT in lane 1, factor Va306 in lane 4, 
factor Va506 in lane 7, and factor Va306/506 in lane 10).  Immediately following activation, 
the factor Va molecules were inactivated with APC.  Factor VaiWT displayed the expected 
fragments of APC inactivation of the cofactor, accumulation of the Mr 30,000 fragment 
(lane 2), and inactivation of the wild type procofactor also shows the Mr 30,000 fragment 
(lane 3).  Factor Va306, which is unable to be cleaved at Arg306, does not get completely 
inactivated and there is no appearance of the Mr 30,000 fragment; following APC 
incubation both factor Vai306 and factor Vi306 display the Mr 75,000 fragment indicating 
only the initial first cleavage at Arg506 (lanes 5 and 6).  Conversely, when the Arg506 APC 
cleavage site is missing in factor Va506 we see only the appearance of the Mr 45,000 
fragment indicating that factor Va506 and factor V506 were only cleaved at Arg306.  
Because cleavage at Arg506 occurs first and is necessary for effective cleavage at Arg306, 
factor Vai506 and factor Vi506 were not fully cleaved at Arg306 (lanes 8 and 9, 
respectively).  On the other hand, the factor Va306/506 and factor V306/506 molecules are 
unable to be inactivated by APC, we do not see any of the APC inactivation fragments 
(lanes 11 and 12, respectively).  These data demonstrate that our recombinant factor V 
mutants display the expected fragments of APC inactivation and can be used to further 
elucidate the molecular mechanism of factor V/Va APC inactivation.   
     4.4.3 Clotting Activity of Recombinant Factor V/Va Molecules Following APC 
Inactivation in the Presence of a Membrane Surface 
     Next, we analyzed the factor V recombinant molecules with the APC inactivating 
cleavage sites mutated for their clotting activity.  Clotting times were recorded before the 
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Figure 4.2 Western Blot Analysis of Recombinant Factor V Molecules with an 
Antibody Specific to the Heavy Chain of Factor Va.  Recombinant Factor V molecules 
were subjected to activation by thrombin and inactivation by APC in the presence of a 
membrane surface.  The molecules were incubated with APC and PCPS with or without 
activation with thrombin.  The lane assignments are as follows; Lane 1 factor VaWT, Lane 
2 factor VaiWT, Lane 3 factor ViWT, Lane 4 factor Va306, Lane 5 factor Vai306, Lane 6 
factor Vi306, Lane 7 factor Va506, Lane 8 factor Vai506, Lane 9 factor Vi506, Lane 10 factor 
Va306/506, Lane 11 factor Vai306/506, and Lane 12 factor Vi306/506. 
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addition of a membrane surface and APC and following 15 and 30 minutes of APC 
incubation and the results are shown in Figure 4.3.  All factor V and factor Va species are 
able to produce a clot at the expected times, 20-25 seconds for the factor V species and 
16-18 seconds for the factor Va species.  Following 15 minutes of APC inactivation in 
the presence of a membrane surface, factor VaiWT and factor ViWT have clotting times 
increased to 60 and 80 seconds , respectively, and following 30 minutes of inactivation 
the wild type factor Vai and factor Vi have further increased clotting times of 90 and 100 
seconds, respectively.  This demonstrates that the wild type molecule is fully inactivated, 
even after a 15 minute incubation with APC and PCPS and that the procofactor and 
activated cofactor behave similarly during inactivation.  Factor Vi306 and factor Vai306 
behave like the wild type molecules, the molecules are completely inactivated following 
APC inactivation in the presence of a membrane surface having clotting times over 75 
seconds.  On the other hand, when factor V306 is activated with thrombin before 
inactivation, the factor Vai306 molecule does not get completely activated and still retains 
a clotting time of approximately 45 seconds even after 30 minutes of incubation with 
APC and PCPS.  Suggesting that the mechanism of APC inactivation of factor V/Va with 
the Arg306 cleavage site mutated is different between the procofactor and active cofactor.  
Conversely, factor V506 and factor Va506 have comparable clotting times when exposed to 
APC and a membrane surface.  These recombinant molecules retain partial activity even 
after a 30 minute incubation.  Since factor Va306/506 does not contain the APC inactivating 
cleavage sites at Arg306 and Arg506 it is not susceptible to APC inactivation as evidenced 
by unchanging clotting times.  On the contrary, similar to factor Vi306, factor Vi306/506 does 
not behave like the activated version of the mutant.  Its clotting  
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Figure 4.3 Time Course of Clotting Times.  Clotting times were measured as described 
in ‘Experimental Procedures’.  The recombinant factor V/Va molecules were analyzed 
prior to APC inactivation in the presence of a membrane surface and following 15 and 30 
minute incubation times. 
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times are increased to 30 seconds following incubation with APC.  These data 
demonstrate that upon thrombin activation of factor V306 and removal of the B chain of 
the procofactor, it causes APC inactivation to proceed at a different rate. 
4.4.4 Factor Va/Vai Titrations 
     In order to test the ability of the recombinant factor Va and factor Vai to assemble in 
the prothrombinase complex, effectively bind the enzyme, and activate prothrombin an 
assay using purified reagents and a chromogenic substrate was used.  The results with the 
recombinant factor V molecules activated were as expected.  Figure 4.4 and Table 4.2 
demonstrate that factor VaWT (filled squares), factor Va306 (filled inverted triangles), 
factor Va506 (filled triangles), and factor Va306/506 (filled circles) have similar kd values, 
indicating the mutations do not affect the interaction between factor Va and factor Xa.  
We also analyzed the effect of APC inactivation of the recombinant cofactors.  
Inactivation of the wild type cofactor does not have any effect on the affinity with the 
enzyme (open squares).  On the other hand, the mutated cofactors have a decreased 
affinity for factor Xa.  Factor Vai306 has a 9-fold increase in the kd (open inverted 
triangles), factor Vai506 has a 8-fold increase in the kd (open triangles), and factor 
Vai306/506 has a 5-fold increase in the kd (open circles).  These data demonstrate that 
partial inactivation of the factor Va when its APC inactivation sites are mutated results in 
a molecule that has a decreased affinity for the enzyme in the prothrombinase complex. 
4.4.5 Prothrombin Titrations with Limiting Concentrations of Factor Xa 
     Next the ability of the recombinant factor Va molecules to assemble in the 
prothrombinase complex and activate prothrombin using kinetic experiments designed to 
determine the Km and kcat values for prothrombinase function.  These experiments were  
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Figure 4.4 Factor Va Titrations. Thrombin generation experiments were carried out as 
described under “Experimental Procedures”.  Prothrombinase complex assembled with 
varying concentrations (30 pM to 5 nM) of purified recombinant factor VaWT (closed 
squares), factor VaiWT (open squares), factor Va306 (closed inverted triangles), factor 
Vai306 (open inverted triangles), factor Va506 (closed triangles), factor Vai506 (open 
triangles), factor Va306/506 (closed circles), and factor Vai306/506 (open circles).  The solid 
lines represent a nonlinear regression fit of the data using Prizm GraphPad software for a 
one binding site model.  Titrations were performed in triplicate with at least three 
different preparations of purified purified protein. 
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performed in the presence of limiting amounts of factor Xa (5-10pM) and the 
concentration of the cofactor was kept constant (10nM) while the substrate concentration 
was varied (25nM to 4µM).  The results are shown in Figure 4.4 and Table 4.2 and 
demonstrate that factor VaWT (filled squares), factor Va306 (filled inverted triangles), 
factor Va506 (filled triangles), and factor Va306/506 (filled circles) have similar Km values 
indicated similar affinities for the substrate, prothrombin.  Factor Vai506 (open triangles) 
and factor Vai306/506 (open circles) also have Km values close to the wild type factor Va.  
These results suggest cleavage that the first cleavage at Arg506 does not have an effect on 
binding the substrate.  However, when the cleavage site at Arg306 is not present in factor 
Vai306 (open inverted triangles) and it can only be cleaved at Arg506, it causes a slight 
decrease in the affinity for the substrate.  Likewise, factor Vai306/506 (open circles) also 
has an increased Km value.   
     The catalytic efficiencies were also calculated from the prothrombin titrations with 
limiting concentrations of factor Xa and the results are shown in Figure 4.5.  The results 
show that all the recombinant factor Va/Vai species with the exception of factor VaiWT 
and factor Vai506 have similar kcat values compared to the wild type cofactor in the 
presence of APC under the experimental conditions used.  Factor VaiWT has a 
dramatically decreased catalytic efficiency as to be expected, with a 40-fold reduction in 
the kcat, while factor Vai506 only had a 2-fold reduction in the catalytic efficiency of 
prothrombin activation.  
4.4.6 Prothrombin Titrations with Limiting Concentrations of Factor Va/Vai 
     Next, the ability of limiting concentrations of the recombinant factor V/Va molecules 
before and after APC inactivation in the presence of excess amounts of the enzyme, 
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Figure 4.5 Prothrombin Titrations with Limiting Concentration of Factor Xa.  
Thrombin generation experiments were carried out as described under “Experimental 
Procedures” by varying the substrate concentration (25 nM to 4 µM) with 5 pM of factor 
Xa saturated with the factor Va species.  Prothrombinase complex assembled with 
recombinant purified wild type factor Va (filled squares), factor VaiWT (open squares), 
factor Va306 (closed inverted triangles), factor Vai306 (open inverted triangles), factor 
Va506 (closed triangles), factor Vai506 (open triangles), factor Va306/506 (closed circles), 
and factor Vai306/506 (open circles).  The data shown are the average of three different 
titrations performed in triplicate with at least three different preparations of purified 
proteins.   
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Figure 4.6 Prothrombin Titrations with Limiting Concentration of Factor Va.  
Thrombin generation experiments were carried out as described under “Experimental 
Procedures” by varying the substrate concentration (25 nM to 4 µM) with 10 nM of 
factor Xa saturated with the factor Va species.  Prothrombinase complex assembled with 
recombinant purified wild type factor Va (filled squares), factor VaiWT (open squares), 
factor Va306 (closed inverted triangles), factor Vai306 (open inverted triangles), factor 
Va506 (closed triangles), factor Vai506 (open triangles), factor Va306/506 (closed circles), 
factor Vai306/506 (open circles), and factor Xa alone (closed diamonds).  The data shown 
are the average of three different titrations performed in triplicate with at least three 
different preparations of purified proteins.   
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0.414 0.262 0.121 Factor Va506 
0.569 0.182 0.755 Factor Vai306/506 
0.932  0.149 0.299 Factor Va306/506 
0.975 0.189 1.09 Factor Vai506 
0.497 0.175 1.24 Factor Vai306 
0.606 1.13 0.301 Factor Va306 
0.506 0.535 0.143 Factor VaiWT 
0.674 0.131 0.221 Factor VaWT 
Km (µM) with 
Limiting Factor Va 
Km (µM) with 
Limiting Factor Xa 
Kd (nM) Recombinant 
Factor V Species 
 
 
 
 
 
Table 4.2 Kinetic Constants of Recombinant Factor Va Species Before and After 
APC Inactivation.  The dissociation constants of recombinant factor Va species for 
plasma derived factor Xa were calculated at limiting concentrations of the enzyme as 
described in “Experimental Procedures”.  The Km constants were determined at described 
in “Experimental Procedures” using limiting amounts of the enzyme and varying 
concentrations of substrate. 
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factor Xa, were studied in an assay employing purified reagents and a chromogenic 
substrate that probes for thrombin generation.  Recent data have shown that in the 
presence of excess amounts of the enzyme and limiting amounts of the cofactor in the 
prothrombinase complex results in an enzymatic complex that cleaves prothrombin first 
at Arg271 and has an approximate 5-fold decrease in the affinity for the substrate 
(nesheim, unpublished data).  Our results are consistent with these findings.  Factor 
VaiWT, factor Vai306, factor Vai506, and factor Vai306/506 show approximately a 5-fold 
decrease or more in the affinity for the substrate under the experimental conditions used.   
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Figure 4.7 Comparison of kcat Values of Recombinant Factor Va Species Before and 
After APC Inactivation.  The values of kcat were determined using the kd’s and the 
quadratic equation to determine the saturation concentration of the various recombinant 
factor Va species. 
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4.5 Discussion 
     Proteolytic inactivation of factor Va by APC requires a membrane surface and 
cleavage at both Arg506 and Arg306 located in the heavy chain of the active cofactor.  Our 
data demonstrate that inactivation of the procofactor, factor V, and the active cofactor, 
factor Va, occur at different kinetic rates at the different inactivation cleavages.  The 
proteolytic inactivation of factor V/Va at Arg306 appears to occur at different rates in the 
presence of a membrane surface.  When the cleavage site at Arg306 is mutated to a 
glutamine residue it can no longer be cleaved by APC.  Analysis of clotting times of 
factor Vai306 and factor Vi306 demonstrate that the inactivation of the active molecule 
occurs much slower and retains clotting activity after 30 minutes of incubation with APC 
in the presence of a membrane surface.  On the other hand, inactivation of the procofactor 
molecule with the mutation at Arg306 results in a recombinant molecule with greatly 
decreased clotting activity in the presence of APC and a membrane surface even after 
only 15 minutes of incubation.   
     It has long been established that a single point mutation in the factor V gene which 
results in a Arg506 to Gln replacement is a common risk factor for thrombosis and caused 
APC resistance in patients.  It has been demonstrated in the literature and our present data 
support that cleavage at Arg506 does not result in complete inactivation of factor Va and 
that Arg306 is required for complete inactivation of the cofactor by APC.  Therefore, one 
would presume that mutation at Arg306 would cause a severe APC resistance leading to a 
thrombotic state.  On the contrary, patients with this amino acid residue mutated, factor 
VCAMBRIDGE (with a Arg306 to Thr mutation) and factor VHONGKONG (with a Arg306 to Gly 
mutation), do not appear to be at high risk for thrombosis. 
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     The double mutant, factor V306/506 was vastly resistant to APC inactivation with no 
considerable loss of cofactor activity under all conditions tested herein.  Western blot 
analysis showed no heavy chain fragments when the cofactor and active cofactor 
molecules were exposed to APC in the presence of a membrane surface.  This clearly 
demonstrates the importance of APC cleavage sites at Arg306 and Arg506 and that 
cleavage at Arg679 does not play a role in APC inactivation of factor Va under the 
experimental conditions employed.  This could be because cleavage at Arg679 does not 
occur in the absence of cleavage at Arg306 and Arg506 or it does not contribute to 
inactivation. 
     There are conflicting results described in the literature in relation to the cleavage sites 
of APC catalyzed inactivation of factor Va.  Kolfschoten et al. report that factor Va can 
be inactivated by APC in the absence of cleavage site at Arg306, Arg506, and Arg679 (22).  
This laboratory constructed recombinant factor V molecules with the cleavage sites at 
Arg306, Arg506, and Arg679 mutated using constructs with a large portion of the B domain 
deleted claiming the B domain of the cofactor does not play a crucial role in the 
inactivation of factor Va.  This contradicts preliminary data from our laboratory showing 
the importance of the B region in factor Va inactivation (unpublished data).  Their data 
demonstrate that a recombinant molecule with all three APC inactivation cleavage sites 
mutated is still able to be inactivated under their experimental conditions, while our data 
clearly demonstrates the importance of cleavage at Arg306 and Arg506.  This difference 
could be in the experimental conditions used to inactivate the cofactor with APC; our 
laboratory uses small concentrations of thrombin to activate the procofactor and small 
concentrations of APC to inactivate the active cofactor with a 30 minute incubation time, 
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whereas their laboratory uses large amounts of thrombin and APC in their experiments 
with a three hour incubation time.  This difference in enzyme concentrations may explain 
the dramatic difference in results; spontaneous degradation of the purified recombinant 
cofactor cannot be ruled out due to their prolonged incubation times.  Moreover, their 
data show a truncated heavy chain with residues 1-643 generated following activation 
with thrombin.  This can be alternatively explained by the fact that under prolonged 
exposure to thrombin, factor Va can further be cleaved at Arg643 (unpublished data, 
Kalafatis et al.).   
     Overall, our data demonstrate the importance of factor Va APC inactivation cleavage 
sites at Arg306 and Arg306/506.  We show a recombinant factor Va molecule with both these 
cleavage sites removed is unable to be proteolyically cleaved by APC in the presence of a 
membrane surface following prolonged exposure. 
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CHAPTER V 
OVERALL CONCLUSION 
 
 
5.1 Overall Conclusion 
     In view of the fact that heart disease is the number one killer of men and women in 
the United States and the current anti-coagulant medical therapies possess many 
serious side effects, more knowledge of the specific molecular mechanisms of the 
proteins involved in the blood coagulation cascade is needed.  The penultimate step in 
the blood coagulation cascade is the activation of prothrombin by the prothrombinase 
complex.  In order to find a better, more specific anti-coagulant drug, we have further 
defined the mechanism by which factor Va exerts its cofactor function and increases 
the catalytic efficiency of the prothrombinase complex.  The advantageous molecular 
mechanisms of factor Va cofactor function are currently unknown.  It has been 
suggested that the binding of factor Va to factor Xa exposes cryptic exosites on the 
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enzyme improving its catalytic function.  One likely mechanism is that the 
incorporation of factor Va into the prothrombinase complex rearranges the enzyme 
and substrate into a position where efficient catalysis can occur.  The residues 
involved in binding to the substrate, prothrombin, may serve as a guide for the design 
of a more specific anti-coagulant drug that only targets the members of the 
prothrombinase complex.  The goal is to reduce the side effects of the current anti-
coagulants on the market. 
     Factor Va binding sites for factor Xa have been identified on both the heavy and 
light chains of the cofactor (16, 32, 37, 112).  While the binding sites on the light 
chain of factor Va remain to be identified, the binding sites on the heavy chain have 
been well studied.  Our laboratory has demonstrated amino acid residues Glu323, 
Tyr324, Glu330, and Val331 located on the A2 domain of the factor Va heavy chain are 
vital for expression of factor Va cofactor activity and contain a binding site for factor 
Xa (112).  In addition, our laboratory has shown that mutation at one or two of the 
factor Xa binding sites has no major consequence on the kinetic parameters of 
prothrombinase assembly and function, however mutation of all four of these residues 
results in a recombinant molecule unable to efficiently convert prothrombin to 
thrombin (131). 
     Collectively, our data presented herein further establish the role of residues from 
the A2 domain of factor Va heavy chain in prothrombinase assembly and function.  
We have established that amino acid residues Glu334 and Tyr335 are necessary for 
optimal rearrangement of the enzyme and substrate for proficient prothrombin 
activation.  Specifically, our data illustrate that substitution of amino acid residues 
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334-335 (factor VaKF and factor VaAA) are enough to have an effect on cofactor 
function, nevertheless it takes mutating four residues (factor VaMI/KF, factor VaMI/AA, 
factor VaFF/KF, and factor VaFF/AA) to entirely eliminate factor Va cofactor activity.  
Kinetic analysis with these molecules show decreased affinity for the enzyme, factor 
Xa, and dramatically reduced catalytic efficiencies. 
     Furthermore, our laboratory has confirmed the COOH-terminal portion of the 
factor Va heavy chain is important for the activation of the procofactor by thrombin 
and its interaction with prothrombin under physiological conditions within the 
prothrombinase complex.  Analysis of a peptide 695DYDYQ699 binds prothrombin in a 
competitive manner with the prothrombinase complex (25).  We examined the ability 
of amino acid motifs 334DY335 and 695DYDY698 to act in concert and allosterically 
regulate prothrombinase assembly and function.  Allosteric regulation is the 
regulation of an enzyme by binding of a cofactor molecule, in this case factor Va, to 
the enzyme at its allosteric site, or a site other than the active site of the molecule.  
Our data presented currently show that recombinant factor Va molecules with 
mutations at the aforementioned residues (factor Va3K, factor VaKF/4A, and factor 
Va6A) have a noteworthy consequence on cofactor activity.  In particular, kinetic 
investigation with these molecules have a decreased catalytic efficiency.  Molecular 
modeling data from our laboratory has also shown that residues 334-335 and 695-698 
are located on the surface of the heavy chain and are in close proximity to each other.  
Taken together these observations support the conclusion that amino acid residues 
334-335 work together with 695-698 and are indispensable to factor Va cofactor 
function and timely activation of prothrombin by the prothrombinase complex. 
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     Since the blood coagulation system has to maintain a delicate balance between 
thrombosis (blood clotting) and haemorrhage (excessive bleeding), the details of the 
down regulation of the coagulation cascade have been under intense investigation.  
Once enough thrombin is produced to form the fibrin plug at the site of vascular 
injury, it activated protein C to its active form, activated protein C (APC).  APC 
subsequently goes on to inactivate factor Va by proteolytic cleavages so it can no 
longer participate in the prothrombinase complex, therefore ceasing thrombin 
production.  Factor Va is cleaved by APC at arginine residues 306, 506, and 679 on 
the heavy chain of the active cofactor.  In addition, the procofactor molecule can also 
be cleaved by APC at residues Arg306, Arg506, Arg679, and Lys994.  Our data 
demonstrate a different rate of inactivation between factor V and factor Va in the 
presence of a membrane surface.  Factor Vai306 retains clotting activity after a 30 
minute incubation APC and lipids; on the other hand, factor Vi306 was rapidly 
inactivated and had a greatly decreased clotting activity even after a 15 minute 
incubation.  These results are consistent with patients that have an Arg306 mutation, in 
that they do not appear to have a high risk for thrombosis.  Overall the data presented 
suggest the significance of APC inactivating cleavages Arg306 and Arg506 on the 
factor Va heavy chain for complete inactivation and the down regulation of the 
coagulation cascade. 
     Overall, the ultimate goal of our research is to define the molecular mechanism of 
the incorporation of factor Va into the prothrombinase complex as it relates to the 
advantageous process of hemostasis and the detrimental phenomena of thrombosis.  
The research presented herein brings us one step closer to this goal, we have shown 
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that the expression of factor Va cofactor activity is required for the rearrangement of 
the enzyme and substrate within the prothrombinase complex necessary for efficient 
prothrombn catalysis.  We expect this research will lead to the design of a specific 
peptide or small molecule that will inhibit the procoagulant activities of thrombin 
production. 
